Teleflex (TFX) 10-Q 2 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 01, 2017	Oct. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 1, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Central Index Key	96,943
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		45,049,267

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Income Statement [Abstract]
Net revenues	$ 534,703	$ 455,648	$ 1,551,197	$ 1,354,094
Cost of goods sold	239,476	214,046	710,126	630,946
Gross profit	295,227	241,602	841,071	723,148
Selling, general and administrative expenses	163,771	139,797	486,674	419,128
Research and development expenses	21,194	15,067	59,299	42,892
Restructuring (credits) charges	(92)	3,027	13,723	12,876
Gain on sale of assets	0	(2,776)	0	(4,173)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	110,354	86,487	281,375	252,425
Interest expense	21,264	12,888	58,884	38,579
Interest income	(286)	(115)	(616)	(324)
Loss on extinguishment of debt	0	0	5,593	19,261
Income from continuing operations before taxes	89,376	73,714	217,514	194,909
Taxes on income from continuing operations	9,978	7,514	19,404	18,134
Income from continuing operations	79,398	66,200	198,110	176,775
Operating (loss) income from discontinued operations	(3,749)	260	(4,597)	(116)
(Benefit) taxes on income (loss) from discontinued operations	(1,366)	138	(1,675)	(119)
(Loss) income from discontinued operations	(2,383)	122	(2,922)	3
Net income	77,015	66,322	195,188	176,778
Less: Income from continuing operations attributable to noncontrolling interest	0	0	0	464
Net income attributable to common shareholders	$ 77,015	$ 66,322	$ 195,188	$ 176,314
Basic:
Income from continuing operations (in dollars per share)	$ 1.76	$ 1.50	$ 4.40	$ 4.09
Income (loss) from discontinued operations (in dollars per share)	(0.05)	0.01	(0.06)	0
Net income (in dollars per share)	1.71	1.51	4.34	4.09
Diluted:
Income from continuing operations (in dollars per share)	1.70	1.40	4.24	3.69
Loss from discontinued operations (in dollars per share)	(0.05)	0	(0.06)	0
Net income (in dollars per share)	1.65	1.40	4.18	3.69
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 1.02	$ 1.02
Weighted average common shares outstanding
Basic (in shares)	45,035	44,045	44,975	43,081
Diluted (in shares)	46,587	47,446	46,673	47,824
Amounts attributable to common shareholders:
Income from continuing operations, net of tax	$ 79,398	$ 66,200	$ 198,110	$ 176,311
(Loss) income from discontinued operations, net of tax	(2,383)	122	(2,922)	3
Net income attributable to common shareholders	$ 77,015	$ 66,322	$ 195,188	$ 176,314

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 77,015	$ 66,322	$ 195,188	$ 176,778
Other comprehensive income (loss), net of tax:
Foreign currency translation, net of tax of $(8,429), $(327), $(26,910), and $(2,978) for the three and nine month periods, respectively	43,345	(130)	156,012	11,088
Pension and other postretirement benefit plans adjustment, net of tax of $(479), $(737), $(1,476) $(2,007) for the three and nine month periods, respectively	743	1,430	2,337	3,914
Derivatives qualifying as hedges, net of tax of $141, $(393), $(1,029), and $212 for the three and nine month periods, respectively	(243)	(223)	4,918	761
Other comprehensive income (loss), net of tax:	43,845	1,077	163,267	15,763
Comprehensive income	120,860	67,399	358,455	192,541
Less: comprehensive income attributable to noncontrolling interest	0	24	0	421
Comprehensive income attributable to common shareholders	$ 120,860	$ 67,375	$ 358,455	$ 192,120

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (8,429)	$ (327)	$ (26,910)	$ (2,978)
Pension and other postretirement benefits plans adjustment, tax	(479)	(737)	(1,476)	(2,007)
Derivatives qualifying as hedges, tax	$ 141	$ (393)	$ (1,029)	$ 212

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Oct. 01, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 1,017,573	$ 543,789
Accounts receivable, net	306,472	271,993
Inventories, net	382,417	316,171
Prepaid expenses and other current assets	51,599	40,382
Prepaid taxes	8,690	8,179
Assets held for sale	0	2,879
Total current assets	1,766,751	1,183,393
Property, plant and equipment, net	374,461	302,899
Goodwill	1,886,157	1,276,720
Intangible assets, net	1,606,943	1,091,663
Deferred tax assets	2,020	1,712
Other assets	44,401	34,826
Total assets	5,680,733	3,891,213
Current liabilities
Current borrowings	77,250	183,071
Accounts payable	85,419	69,400
Accrued expenses	88,095	65,149
Current portion of contingent consideration	591	587
Payroll and benefit-related liabilities	88,091	82,679
Accrued interest	13,430	10,450
Income taxes payable	12,857	7,908
Other current liabilities	8,912	8,402
Total current liabilities	374,645	427,646
Long-term borrowings	2,172,805	850,252
Deferred tax liabilities	471,667	271,377
Pension and postretirement benefit liabilities	116,441	133,062
Noncurrent liability for uncertain tax positions	14,238	17,520
Other liabilities	58,460	52,015
Total liabilities	3,208,256	1,751,872
Commitments and contingencies
Convertible notes - redeemable equity component	0	1,824
Mezzanine equity	0	1,824
Total shareholders' equity	2,472,477	2,137,517
Total liabilities and shareholders' equity	$ 5,680,733	$ 3,891,213

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016
Cash flows from operating activities of continuing operations:
Net income	$ 195,188	$ 176,778
Adjustments to reconcile net income to net cash provided by operating activities:
Loss (income) from discontinued operations	2,922	(3)
Depreciation expense	42,390	40,272
Amortization expense of intangible assets	63,976	47,486
Amortization expense of deferred financing costs and debt discount	3,940	8,506
Loss on extinguishment of debt	5,593	19,261
Gain on sale of assets	0	(4,173)
Fair value step up of acquired inventory sold	10,442	0
Changes in contingent consideration	(109)	1,672
Stock-based compensation	14,519	12,540
Deferred income taxes, net	(15,682)	(8,699)
Other	(13,559)	(15,132)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	6,428	4,316
Inventories	(20,257)	(5,617)
Prepaid expenses and other current assets	(4,009)	1,184
Accounts payable and accrued expenses	24,128	17,390
Income taxes receivable and payable, net	3,798	5,817
Net cash provided by operating activities from continuing operations	319,708	301,598
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(53,977)	(35,912)
Proceeds from sale of assets	6,332	9,792
Payments for businesses and intangibles acquired, net of cash acquired	(1,010,711)	(14,040)
Net cash used in investing activities from continuing operations	(1,058,356)	(40,160)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,963,500	671,700
Reduction in borrowings	(747,576)	(714,487)
Debt extinguishment, issuance and amendment fees	(19,114)	(8,958)
Net proceeds from share based compensation plans and the related tax impacts	4,739	7,647
Payments to noncontrolling interest shareholders	0	464
Payments for contingent consideration	(245)	(133)
Payments for acquisition of noncontrolling interest	0	9,231
Dividends paid	(45,905)	(43,980)
Net cash provided by (used in) financing activities from continuing operations	1,155,399	(97,906)
Cash flows from discontinued operations:
Net cash used in operating activities	(1,140)	(1,451)
Net cash used in discontinued operations	(1,140)	(1,451)
Effect of exchange rate changes on cash and cash equivalents	58,173	(988)
Net increase in cash and cash equivalents	473,784	161,093
Cash and cash equivalents at the beginning of the period	543,789	338,366
Cash and cash equivalents at the end of the period	1,017,573	499,459
Non cash financing activities of continuing operations:
Settlement and exchange of convertible notes with common or treasury stock	53,207	35,205
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$ 127,158	$ 85,909

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning Balance at Dec. 31, 2015					$ (371,124)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 176,778
Other comprehensive income	15,763
Ending Balance at Sep. 25, 2016					(356,150)
Beginning Balance (in shares) at Dec. 31, 2016		45,814				1,741
Beginning Balance at Dec. 31, 2016	2,137,517	$ 45,814	$ 506,800	$ 2,194,593	(438,717)	$ (170,973)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	195,188			195,188
Cash dividends ($1.02 per share)	(45,905)			(45,905)
Other comprehensive income	163,267				163,267
Settlements of convertible notes (in shares)		927				(503)
Settlements of convertible notes	4,831	$ 927	(48,375)			$ 52,279
Settlements of note hedges associated with convertible notes and warrants (in shares)						622
Settlements of note hedges associated with convertible notes and warrants	3		127,158			$ (127,155)
Shares issued under compensation plans (in shares)		119				(46)
Shares issued under compensation plans	17,488	$ 119	15,050			$ 2,319
Deferred compensation (in shares)						(2)
Deferred compensation	88					$ 88
Ending Balance (in shares) at Oct. 01, 2017		46,860				1,812
Ending Balance at Oct. 01, 2017	$ 2,472,477	$ 46,860	$ 600,633	$ 2,343,876	$ (275,450)	$ (243,442)

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 1.02	$ 1.02

Basis of presentation

Basis of presentation	9 Months Ended
	Oct. 01, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements, but, as permitted by Rule 10-01 of Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016 .

New accounting standards

New accounting standards	9 Months Ended
	Oct. 01, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	Note 2 — New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, collectively with related guidance provided by the FASB, is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. The Company will adopt this standard in the first quarter 2018 and expects to use the modified retrospective method of adoption by recognizing the cumulative effect of adopting this guidance as an adjustment to the Company's opening balance of retained earnings at January 1, 2018. Although the Company's evaluation of this guidance is ongoing, based on its assessment to date, the Company believes that the adoption of this guidance will not have a material impact on its consolidated results of operations, cash flows and financial position. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including, among other things, guidance related to accounting for income taxes, modification of the criteria for classification of awards as either equity awards or liability awards where an employer withholds shares from an employee's share-based award for tax withholding purposes, and classification on the statement of cash flows of cash payments to a tax authority by an employer that withholds shares from an employee's award for tax withholding purposes. The Company adopted this guidance as of January 1, 2017. The Company has applied the new guidance requiring recognition of excess tax deficiencies and tax benefits in the income statement, rather than in additional paid-in-capital, as previously required. The adoption of the new standard increased net income and cash flows from operating activities by $1.5 million and $5.9 million and increased diluted earnings per share by $0.03 and $0.13 for the three and nine months ended October 1, 2017 , respectively. The Company will continue to estimate forfeitures of share-based awards at the time of grant, rather than recognize actual forfeitures as they occur, as permitted under the new guidance. In August 2016, the FASB issued new guidance with regard to eight specific issues pertaining to the classification of certain cash receipts and cash payments within the statement of cash flows. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. The new guidance should generally be adopted using a retrospective transition method for each period presented. The Company believes that its adoption of the new guidance will not have a material impact on its cash flows. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. The Company is evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued new guidance to clarify the definition of a “business,” with the objective of assisting entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or as an acquisition of a business. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill and consolidation. The guidance generally defines a business as an integrated set of activities and assets (collectively referred to as a “set”) that is capable of being conducted and managed for the purpose of providing a return to investors or other owners, members, or participants. The guidance further provides that, to be considered a business, a set must meet specified requirements. However, the guidance also states that, if substantially all of the fair value of gross assets acquired (subject to specified exceptions) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and no further analysis is required. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance permits early adoption, and the Company adopted this guidance during the fourth quarter 2017. The Company does not anticipate that the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued guidance to simplify the quantitative test for goodwill impairment. Under current guidance, if a reporting unit’s carrying value exceeds its fair value, the entity must determine the implied value of goodwill. This determination is made by deducting the fair value of a reporting unit’s identifiable assets and liabilities from the fair value of the reporting unit as a whole as if the reporting unit had just been acquired. Under the new guidance, a determination of the implied value of goodwill will no longer be required; a goodwill impairment will be equal to the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The revised guidance is effective for fiscal years, and any interim goodwill impairment tests within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated results of operations and financial position. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Acquisitions

Acquisitions	9 Months Ended
	Oct. 01, 2017
Business Combinations [Abstract]
Acquisitions	Note 3 — Acquisitions On October 2, 2017, the Company acquired NeoTract, Inc. ("NeoTract"). See Note 16, Subsequent events, for additional information related to this acquisition. During the nine months ended October 1, 2017, the Company completed three acquisitions, all of which were accounted for as business combinations. Tianjin Medis Medical Device Co. On September 15, 2017, the Company acquired certain assets from one of its contract manufacturers, Tianjin Medis Medical Co. LTD ("Tianjin Medis"), consisting of substantially all of the assets used by Tianjin Medis to manufacture a line of the Company's laryngeal masks. The aggregate consideration for the assets was $21.3 million , which included payments of $16.0 million and $5.3 million in estimated fair value of contingent consideration. The assets acquired include goodwill and finite-lived intangible assets (consisting of intellectual property, customer lists and a non-compete agreement) of $14.7 million and $6.9 million , respectively. Pyng On April 3, 2017, the Company completed the acquisition of Pyng Medical Corp ("Pyng"), a medical device company that develops and markets sternal intraosseous infusion products, which complement the Company's anesthesia product portfolio. The Company acquired all of the issued and outstanding common shares of Pyng utilizing available cash. The aggregate consideration was $17.9 million , net of cash acquired. The assets acquired include goodwill and finite-lived intangible assets (primarily intellectual property and customer lists) of $13.0 million and $5.5 million , respectively. The goodwill resulting from the acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business. Vascular Solutions On February 17, 2017, the Company completed the acquisition of Vascular Solutions, Inc. (“Vascular Solutions”) pursuant to a merger transaction. Vascular Solutions is a medical device company that develops and markets products for use in minimally invasive coronary and peripheral vascular procedures. In connection with the merger, subject to specified exclusions, each share of common stock of Vascular Solutions (each, a "Share" and collectively, the “Shares”) was converted into the right to receive $56.00 per Share in cash, without interest and subject to applicable withholding tax. In addition, each outstanding option or similar right to purchase Shares issued under the Vascular Solutions’ Stock Option and Stock Award Plan (the "Company Options") was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the acquisition and (ii) the excess, if any, of $56.00 over the exercise price of such Company Option. The aggregate consideration paid by the Company in connection with the merger was approximately $975.5 million , net of cash acquired. For the three and nine months ended October 1, 2017 the Company incurred $0.1 million and $8.3 million , respectively, in transaction expenses associated with the Vascular Solutions acquisition, which are included in selling, general and administrative expenses in the condensed consolidated statement of income. For the three months ended October 1, 2017 , the Company recorded post acquisition revenue and operating profit of $43.9 million and $4.8 million , respectively, related to Vascular Solutions. For the nine months ended October 1, 2017 , the Company recorded post acquisition revenue and operating loss of $110.5 million and $6.8 million , respectively. Financial information of Vascular Solutions is presented within the "All Other" category in the Company's presentation of segment information. The Vascular Solutions acquisition was financed utilizing borrowings under the Amended and Restated Credit Agreement, dated January 20, 2017 (the "Credit Agreement"), which is described in Note 7. The following table presents the purchase price allocation among the assets acquired and liabilities assumed with respect to the Vascular Solutions acquisition: (Dollars in thousands) Assets Current assets $ 63,867 Property, plant and equipment 46,616 Intangible assets 539,250 Goodwill 522,614 Other assets 728 Total assets acquired 1,173,075 Less: Current liabilities 15,079 Deferred tax liabilities 182,472 Liabilities assumed 197,551 Net assets acquired $ 975,524 The Company is continuing to evaluate the initial purchase price allocations, and further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities, certain intangible assets and goodwill. The goodwill resulting from the Vascular Solutions acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired businesses. The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the Vascular Solutions acquisition: Fair value Useful life range (Dollars in thousands) (Years) Intellectual property 248,200 10- 20 In-process research and development ("IPR&D") 15,600 Indefinite Trade names 16,650 20 Customer lists 258,800 25 Pro forma combined financial information The following unaudited pro forma combined financial information for the three and nine months ended October 1, 2017 and September 25, 2016 , respectively, gives effect to the Vascular Solutions acquisition as if it was completed at the beginning of the earliest period presented. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars and shares in thousands, except per share) Net revenue $ 534,703 $ 497,253 $ 1,574,021 $ 1,475,950 Net income $ 76,194 $ 63,578 $ 209,630 $ 136,493 Basic earnings per common share: Net income $ 1.69 $ 1.44 $ 4.66 $ 3.17 Diluted earnings per common share: Net income $ 1.64 $ 1.34 $ 4.49 $ 2.85 Weighted average common shares outstanding: Basic 45,035 44,045 44,975 43,081 Diluted 46,587 47,446 46,673 47,824 The unaudited pro forma combined financial information presented above includes the accounting effects of the Vascular Solutions business combination, including amortization charges from acquired intangible assets, adjustments for depreciation of property, plant and equipment; interest expense; the revaluation of inventory; and the related tax effects. The unaudited pro forma financial information also includes non-recurring charges specifically related to the Vascular Solutions acquisition and interest expense associated with a bridge loan facility that was put in place to, among other things, assist the Company in financing the acquisition of Vascular Solutions. The unaudited pro forma combined financial information for the three and nine months ended September 25, 2016 reflects the historical results of Vascular Solutions for its three and nine months ended September 30, 2016, respectively, and the effects of the pro forma adjustments listed above. 2016 acquisitions The Company made the following acquisitions during 2016 (the "2016 acquisitions"), which, with the exception of its acquisition of the outstanding noncontrolling interest in Teleflex Medical Private Limited, were accounted for as business combinations: • On September 2, 2016, the Company acquired certain assets of CarTika Medical, Inc., ("CarTika"), an original equipment manufacturer (OEM) of catheters and other medical devices that complement the Company's OEM product portfolio. • On July 1, 2016, the Company, which previously owned a 74% controlling interest in its Indian affiliate, Teleflex Medical Private Limited, acquired the remaining 26% ownership interest from the noncontrolling shareholders. Teleflex Medical Private Limited is part of the Company's Asia reportable operating segment. As this acquisition did not result in a change in the Company's control of the entity, the Company recognized the $7.5 million excess of the purchase price of the noncontrolling interest over its carrying value as equity. • During the second quarter 2016, the Company acquired certain assets of two medical device and supplies distributors in New Zealand. The aggregate purchase price paid in connection with the 2016 acquisitions was $22.8 million . The results of operations of the acquired businesses and assets are included in the condensed consolidated statements of income from their respective acquisition dates. Pro forma information is not presented, as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring (credits) charges

Restructuring (credits) charges	9 Months Ended
	Oct. 01, 2017
Restructuring and Related Activities [Abstract]
Restructuring charges	Note 4 — Restructuring (credits) charges The following tables provide information regarding restructuring (credits) charges recognized by the Company for the three and nine months ended October 1, 2017 and September 25, 2016 : Three Months Ended October 1, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ (319 ) $ — $ — $ 58 $ (261 ) 2017 EMEA restructuring program (714 ) — — 84 (630 ) 2016 Footprint realignment plan 274 72 — 85 431 2014 Footprint realignment plan 197 46 — 6 249 Other restructuring programs (1) 8 — 104 7 119 Total restructuring (credits) charges $ (554 ) $ 118 $ 104 $ 240 $ (92 ) Three Months Ended September 25, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Other Restructuring programs $ 1,713 $ — $ — $ — $ 1,713 2016 Footprint realignment plan 851 — — 74 925 2014 Footprint realignment plan 308 — — 6 314 Other restructuring programs (2) (88 ) 54 107 2 75 Total restructuring charges $ 2,784 $ 54 $ 107 $ 82 $ 3,027 Nine Months Ended October 1, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 4,534 $ — $ — $ 92 $ 4,626 2017 EMEA restructuring program 5,822 — — 84 5,906 2016 Footprint realignment plan 1,099 94 (75 ) 214 1,332 2014 Footprint realignment plan 379 60 — 7 446 Other restructuring programs (3) 973 58 313 69 1,413 Total restructuring charges $ 12,807 $ 212 $ 238 $ 466 $ 13,723 Nine Months Ended September 25, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Other Restructuring programs $ 1,713 $ — $ — $ — $ 1,713 2016 Footprint realignment plan 10,919 — — 360 11,279 2014 Footprint realignment plan (118 ) — — 17 (101 ) Other restructuring programs (4) (487 ) $ 232 $ 114 126 (15 ) Total restructuring charges $ 12,027 $ 232 $ 114 $ 503 $ 12,876 (1) Other restructuring programs include the 2017 Pyng Integration program and the 2016 Other Restructuring programs. The Company committed to the 2017 Pyng Integration program, which relates to the integration of Pyng into Teleflex, during the second quarter 2017. (2) Other restructuring programs include the 2015 Restructuring programs and the 2014 European Restructuring Plan. (3) Other restructuring programs include the 2017 Pyng Integration program, the 2016 Other Restructuring programs, the 2015 Restructuring programs and the 2014 European Restructuring plan. (4) Other restructuring programs include the 2014 European Restructuring Plan and the 2012 Restructuring program. 2017 Vascular Solutions Integration Program During the first quarter 2017, the Company committed to a restructuring program related to the integration of Vascular Solutions into Teleflex. The program commenced in the first quarter 2017 and is expected to be substantially completed by the end of the second quarter 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $6.0 million to $7.5 million related to this program, of which $4.5 million to $5.3 million will constitute termination benefits, while $1.5 million to $2.2 million will relate to other exit costs, including employee relocation and outplacement costs. Additionally, the Company expects to incur $2.5 million to $3.0 million of restructuring related charges consisting primarily of retention bonuses offered to certain employees expected to remain with the Company after completion of the program. All of these charges will result in future cash outlays. As of October 1, 2017 , the Company has a restructuring reserve of $1.7 million related to this program. 2017 EMEA Restructuring Program During the first quarter 2017, the Company committed to a restructuring program to centralize certain administrative functions in Europe. The program commenced in the second quarter 2017 and is expected to be substantially completed by the end of 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $7.1 million to $8.5 million related to this program, almost all of which constitute termination benefits, and all of which will result in future cash outlays. As of October 1, 2017 , the Company has a restructuring reserve of $6.0 million related to this program. 2016 Other Restructuring Programs During 2016, the Company committed to programs designed to improve operating efficiencies and reduce costs. The programs involve the consolidation of certain global administrative functions and manufacturing operations. The programs commenced in the second half of 2016 and are expected to be substantially complete by the end of the first quarter 2018. The Company estimates that it will record aggregate pre-tax charges of $3.8 million to $4.7 million related to these programs, substantially all of which constitute termination benefits that will result in future cash outlays. Additionally, the Company expects to incur approximately $1.5 million of accelerated depreciation and other costs directly related to these programs, which the Company anticipates will be recognized in cost of goods sold. Approximately $1.0 million of these costs are expected to result in future outlays. As of October 1, 2017 , the Company has a restructuring reserve of $0.8 million related to these programs. 2016 Footprint Realignment Plan In 2016, the Company initiated a restructuring plan (the “2016 footprint realignment plan") designed to reduce costs, improve operating efficiencies and enhance the Company’s long term competitive position. The plan involves the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 footprint realignment plan of between approximately $34 million to $44 million , of which an estimated $27 million to $31 million are expected to result in future cash outlays. Most of these charges, and the related cash outlays, are expected to be made prior to the end of 2018. In addition to the restructuring charges shown in the tables above, the Company recorded charges related to the 2016 footprint realignment plan of $1.4 million and $5.5 million for the three and nine months ended October 1, 2017 , respectively, and $1.9 million and $4.2 million for the three and nine months ended September 25, 2016 , respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations. As of October 1, 2017 , the Company has incurred restructuring charges in connection with the 2016 footprint realignment plan aggregating to $13.8 million . Additionally, as of October 1, 2017 , the Company has incurred restructuring related charges aggregating to $12.0 million related to the 2016 footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. These costs primarily were included in cost of goods sold. As of October 1, 2017 , the Company has a restructuring reserve of $7.9 million related to this plan, the majority of which relates to termination benefits. 2014 Footprint Realignment Plan In 2014, the Company initiated a restructuring plan (“the 2014 footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 footprint realignment plan of approximately $43 million to $48 million , of which an estimated $33 million to $38 million are expected to result in future cash outlays. The Company expects to incur $24 million to $30 million in aggregate capital expenditures under the plan. In addition to the restructuring charges set forth in the tables above, the Company recorded charges related to the 2014 footprint realignment plan of $1.0 million and $3.1 million for the three and nine months ended October 1, 2017 , respectively, and $2.5 million and $6.9 million for the three and nine months ended September 25, 2016 , respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations. As of October 1, 2017 , the Company has incurred restructuring charges in connection with the 2014 footprint realignment plan aggregating to $11.5 million . Additionally, as of October 1, 2017 , the Company has incurred restructuring related charges aggregating to $25.9 million related to the 2014 footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of October 1, 2017 , the Company has a restructuring reserve of $4.2 million in connection with the plan, all of which relates to termination benefits. For additional information regarding the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. Restructuring (credits) charges by reportable operating segment, and by all other operating segments in the aggregate, for the three and nine months ended October 1, 2017 and September 25, 2016 are set forth in the following table: Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Dollars in thousands) Restructuring (credits) charges Vascular North America $ 606 $ 960 $ 1,715 $ 5,474 Anesthesia North America 220 946 1,031 3,185 Surgical North America — 277 — 257 EMEA (632 ) 89 6,503 3,012 OEM — 187 — 191 All other (286 ) 568 4,474 757 Total restructuring (credits) charges $ (92 ) $ 3,027 $ 13,723 $ 12,876

Inventories, net

Inventories, net	9 Months Ended
	Oct. 01, 2017
Inventory Disclosure [Abstract]
Inventories, net	Note 5 — Inventories, net Inventories as of October 1, 2017 and December 31, 2016 consisted of the following: October 1, 2017 December 31, 2016 (Dollars in thousands) Raw materials $ 98,322 $ 65,319 Work-in-process 60,020 54,555 Finished goods 224,075 196,297 Inventories, net $ 382,417 $ 316,171

Goodwill and other intangible a

Goodwill and other intangible assets, net	9 Months Ended
	Oct. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 6 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the nine months ended October 1, 2017 : Vascular Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) Balance as of December 31, 2016 $ 345,546 $ 141,253 $ 250,912 $ 290,041 $ 138,185 $ 4,883 $ 105,900 $ 1,276,720 Goodwill related to acquisitions — 15,594 — 9,139 2,927 — 522,614 550,274 Currency translation and other adjustments (1,590 ) 458 — 33,665 8,585 — 18,045 59,163 Balance as of October 1, 2017 $ 343,956 $ 157,305 $ 250,912 $ 332,845 $ 149,697 $ 4,883 $ 646,559 $ 1,886,157 The following table provides information as of October 1, 2017 and December 31, 2016 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets: Gross Carrying Amount Accumulated Amortization October 1, 2017 December 31, 2016 October 1, 2017 December 31, 2016 (Dollars in thousands) Customer relationships $ 901,367 $ 622,428 $ (269,447 ) $ (239,055 ) In-process research and development 34,296 16,532 — — Intellectual property 778,292 519,962 (238,236 ) (203,390 ) Distribution rights 23,637 23,021 (16,663 ) (15,239 ) Trade names 408,362 379,724 (18,343 ) (13,974 ) Non-compete agreements 5,354 2,692 (1,676 ) (1,038 ) $ 2,151,308 $ 1,564,359 $ (544,365 ) $ (472,696 )

Borrowings

Borrowings	9 Months Ended
	Oct. 01, 2017
Debt Disclosure [Abstract]
Borrowings	Note 7 — Borrowings The Company's borrowings at October 1, 2017 and December 31, 2016 were as follows: October 1, 2017 December 31, 2016 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 3.24% at October 1, 2017, due 2022 $ 841,000 $ 210,000 Term loan facility, at a rate of 3.24% at October 1, 2017, due 2022 721,000 — 3.875% Convertible Senior Subordinated Notes due 2017 — 136,076 4.875% Senior Notes due 2026 400,000 400,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 1.98% at October 1, 2017 50,000 50,000 2,262,000 1,046,076 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 — (2,707 ) Less: Unamortized debt issuance costs (11,945 ) (10,046 ) 2,250,055 1,033,323 Current borrowings (77,250 ) (183,071 ) Long-term borrowings $ 2,172,805 $ 850,252 Amended and restated senior credit facility On January 20, 2017, the Company entered into the Credit Agreement, which provides for a five year revolving credit facility of $1.0 billion and a term loan facility of $750.0 million . The obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of the material domestic subsidiaries of the Company and are secured by a lien on substantially all of the assets owned by the Company and each guarantor. The maturity date of the revolving credit facility under the Credit Agreement is January 20, 2022, and the term loan facility will mature on February 17, 2022. At the Company’s option, loans under the Credit Agreement will bear interest at a rate equal to adjusted LIBOR plus an applicable margin ranging from 1.25% to 2.50% or at an alternate base rate, which generally is defined as the highest of (i) the publicly announced prime rate of JPMorgan Chase Bank, N.A., the administrative agent under the Credit Agreement, (ii) 0.5% above the federal funds rate and (iii) 1% above adjusted LIBOR for a one month interest period, plus an applicable margin ranging from 0.25% to 1.50% , in each case subject to adjustment based on the Company’s consolidated total leverage ratio (generally, Consolidated Total Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA, as defined in the Credit Agreement, for the four most recent fiscal quarters ending on or preceding the date of determination). Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00% . The Company is required to maintain a total consolidated leverage ratio of not more than 4.50 to 1.00 and a consolidated senior secured leverage ratio (generally, Consolidated Senior Secured Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA for the four most recent quarters ending on or preceding the date of determination) of not more than 3.50 to 1.00. The Company is further required to maintain a consolidated interest coverage ratio (generally, Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination to Consolidated Interest Expense, as defined in the Credit Agreement, paid in cash for such period) of not less than 3.50 to 1.00. The Company capitalized $12.0 million related to transaction fees, including underwriters’ discounts and commissions, incurred in connection with the Credit Agreement. In addition, because the Company's entry into the Credit Agreement was considered a partial extinguishment of the indebtedness under its previously outstanding credit agreement, the Company recognized a loss on extinguishment of debt of $0.4 million during the first quarter 2017. 3.875% Convertible Senior Subordinated Note s Exchange Transactions On January 5, 2017, pursuant to separate, privately negotiated agreements between the Company and certain holders (the "Holders") of its 3.875% Convertible Senior Subordinated Notes due 2017 (the "Convertible Notes"), the Company paid cash and common stock (the "Exchange Consideration") to the Holders in exchange for $91.7 million aggregate principal amount of the Convertible Notes (the "Exchange Transactions"). The Exchange Consideration paid to each of the Holders per $1,000 principal amount of Convertible Notes was equal to: (i) $1,000 in cash, (ii) a number of shares of the Company's common stock equal to the amount of the conversion value of the Convertible Notes in excess of the $1,000 principal amount (the "Conversion Shares"), calculated on the basis of the average daily volume weighted average price per share of Company common stock over a specified period (the "Average Daily VWAP"), (iii) an inducement payment in additional shares of common stock (the "Inducement Shares") calculated based on the Average Daily VWAP; and (iv) cash in an amount equal to accrued and unpaid interest to, but not including, the closing date. As a result of the Exchange Transactions, the Company paid the Holders aggregate cash consideration of approximately $93.2 million (which includes approximately $1.5 million in accrued but previously unpaid interest) and issued and delivered to the Holders approximately 0.93 million shares of Company common stock (including both Conversion Shares and Inducement Shares). The Company funded the $93.2 million cash payment constituting part of the Exchange Consideration through borrowings under its revolving credit facility. As a result of the Exchange Transactions, the Company recognized a loss on extinguishment of debt of $5.2 million during the first quarter 2017. In connection with its entry into the Exchange Transactions, the Company also entered into bond hedge unwind agreements (the "Hedge Unwind Agreements") and warrant unwind agreements (the "Warrant Unwind Agreements") with the dealer counterparties to the convertible note hedge transactions and warrant transactions that were effected at the time of the initial issuance of the Convertible Notes. Under the Hedge Unwind Agreements, the number of then-outstanding call options issued to the Company under the Convertible Note hedge transactions (the "Call Options") was reduced to reflect proportionately the reduction in the outstanding principal amount of the Convertible Notes following the Exchange Transactions. Under the Warrant Unwind Agreements, the number of warrants then held by the dealer counterparties also was reduced. On a net basis, after giving effect to the Hedge Unwind Agreements and Warrant Unwind Agreements, the Company received 0.12 million shares of Company common stock from the dealer counterparties. Settlement and Conversions Upon Maturity The Convertible Notes matured on August 1, 2017 (the "Maturity Date"). On the Maturity Date, the Company repaid the remaining $44.3 million in aggregate principal amount of the Convertible Notes outstanding, together with unpaid interest due and owing on the Convertible Notes (the “Cash Payment”). In connection with the maturity of the Convertible Notes, $44.2 million in aggregate principal amount of the Convertible Notes were tendered to the Company for conversion (the "Converted Notes"). On the Maturity Date, in addition to the Cash Payment, the Company delivered to the holders of the Converted Notes, in the aggregate, 0.5 million shares of Company common stock. In connection with the conversions described above, the Company exercised the outstanding Call Options, and the counterparties to the Convertible Note hedge transactions delivered to the Company 0.5 million shares of Company common stock. The counterparties continue to hold warrants to purchase Company common stock that they acquired at the time of the initial issuance of the Convertible Notes. At October 1, 2017, the warrants, which entitle the holders to purchase 724,648 shares at an exercise price of $74.65 per share, had an intrinsic value of $121.3 million . The warrants are divided into components that expire ratably over a 180 day period commencing November 1, 2017 . Fair Value of Long-Term Borrowings The following table provides information regarding the fair value of the Company’s debt as of October 1, 2017 and December 31, 2016 , categorized by the level of inputs within the fair value hierarchy used to measure fair value: October 1, 2017 December 31, 2016 (Dollars in thousands) Level 1 $ — $ 344,765 Level 2 2,254,376 929,362 Total $ 2,254,376 $ 1,274,127 To determine the fair value of the debt categorized as Level 2 in the table above, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve.

Financial instruments

Financial instruments	9 Months Ended
	Oct. 01, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Note 8 — Financial instruments Foreign Currency Forward Contracts The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage near term foreign currency denominated monetary assets and liabilities. For the three and nine months ended October 1, 2017 , the Company recognized a loss related to non-designated foreign currency forward contracts of $0.6 million and $3.7 million , respectively. For the three and nine months ended September 25, 2016 , the Company recognized a loss related to non-designated foreign currency forward contracts of $0.1 million and $1.7 million , respectively. The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of October 1, 2017 and December 31, 2016 : October 1, 2017 December 31, 2016 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 1,684 $ 667 Non-designated foreign currency forward contracts 318 490 Prepaid expenses and other current assets $ 2,002 $ 1,157 Total asset derivatives $ 2,002 $ 1,157 Liability derivatives: Designated foreign currency forward contracts $ 237 $ 2,139 Non-designated foreign currency forward contracts 93 118 Other current liabilities $ 330 $ 2,257 Total liability derivatives $ 330 $ 2,257 The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of October 1, 2017 and December 31, 2016 was $76.1 million and $101.8 million , respectively. The total notional amount for all open non-designated foreign currency forward contracts as of October 1, 2017 and December 31, 2016 was $112.3 million and $73.4 million , respectively. All open foreign currency forward contracts as of October 1, 2017 have durations of twelve months or less. There was no ineffectiveness related to the Company’s cash flow hedges during the three and nine months ended October 1, 2017 and September 25, 2016 . Concentration of Credit Risk Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the creditworthiness of those countries and the financial stability of their economies. Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at October 1, 2017 and December 31, 2016 : October 1, 2017 December 31, 2016 (Dollars in thousands) Allowance for doubtful accounts (1) $ 10,084 $ 8,630 Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal (2) $ 50,613 $ 51,098 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 16.9 % 19.3 % (1) The current portion of the allowance for doubtful accounts was $3.1 million and $2.0 million as of October 1, 2017 and December 31, 2016 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at October 1, 2017 and December 31, 2016 was $3.5 million and $2.7 million , respectively. In January 2017, the Company sold $16.1 million of receivables outstanding with respect to publicly funded hospitals in Italy for $16.0 million . For the nine months ended October 1, 2017 and September 25, 2016 , net revenues from customers in Greece, Italy, Spain and Portugal were $96.0 million and $95.8 million , respectively.

Fair value measurement

Fair value measurement	9 Months Ended
	Oct. 01, 2017
Fair Value Disclosures [Abstract]
Fair value measurement	Note 9 — Fair value measurement For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016 . The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of October 1, 2017 and December 31, 2016 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,563 $ 8,563 $ — $ — Derivative assets 2,002 — 2,002 — Derivative liabilities 330 — 330 — Contingent consideration liabilities (1) 12,117 — — 12,117 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 7,660 $ 7,660 $ — $ — Derivative assets 1,157 — 1,157 — Derivative liabilities 2,257 — 2,257 — Contingent consideration liabilities (1) 7,102 — — 7,102 (1) As of October 1, 2017 and December 31, 2016, (a) $0.6 million of contingent consideration liabilities were recognized in the current portion of contingent consideration, and (b) $11.5 million and $6.5 million of contingent consideration liabilities, respectively, were recognized in other liabilities in the condensed consolidated balance sheet. There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the nine months ended October 1, 2017 . The following table provides information regarding changes, during the nine months ended October 1, 2017 , in Level 3 financial liabilities related to contingent consideration, which are described below in this Note 9 under "Valuation Techniques": Contingent consideration 2017 (Dollars in thousands) Balance - December 31, 2016 $ 7,102 Additions (1) 5,369 Payment (245 ) Revaluations (109 ) Balance - October 1, 2017 $ 12,117 (1) The Company established a liability related to the estimated fair value of contingent consideration associated with the Tianjin Medis acquisition. Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities as of the measurement date, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company determines the fair value of the liabilities for contingent consideration based on discounted cash flow analysis. This fair value measurement is based on significant inputs unobservable in the market, primarily estimated sales royalties and the discount rate and, therefore, constitutes a Level 3 measurement within the fair value hierarchy.

Shareholders' equity

Shareholders' equity	9 Months Ended
	Oct. 01, 2017
Equity [Abstract]
Shareholders' equity	Note 10 — Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Shares in thousands) Basic 45,035 44,045 44,975 43,081 Dilutive effect of share-based awards 934 639 873 574 Dilutive effect of 3.875% Convertible Notes and warrants (1) 618 2,762 825 4,169 Diluted 46,587 47,446 46,673 47,824 (1) The reduction in the dilutive effect of the Convertible Notes and warrants during the three and nine months ended October 1, 2017 as compared to three and nine months ended September 25, 2016 is due principally to the Company’s repurchase of Convertible Notes and conversions by holders of the Convertible Notes. The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.6 million for the three and nine months ended October 1, 2017 and 1.4 million and 3.9 million for the three and nine months ended September 25, 2016 , respectively. In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge, consisting of call options held by the Company, economically reduced the dilutive impact of the Convertible Notes. However, applicable accounting guidance requires the Company to separately address the dilutive impact of the warrants issued under the warrant agreements in computing diluted weighted average number of common shares outstanding, without giving effect to the anti-dilutive impact of the call options. The reduction in the weighted average number of diluted shares that would result from giving effect to the anti-dilutive impact of the call options would have been 0.1 million and 0.4 million for the three and nine months ended October 1, 2017 , respectively, and 1.5 million and 2.3 million for the three and nine months ended September 25, 2016 , respectively. The treasury stock method is applied to the warrants because the average market price of the Company's common stock during the reporting periods presented exceeds the warrant exercise price of $74.65 per share, and assumes the proceeds from the exercise of the warrants are used by the Company to repurchase shares based on such average market price. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 0.5 million for the three and nine months ended October 1, 2017 and 1.3 million and 1.9 million for the three and nine months ended September 25, 2016 , respectively. The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended October 1, 2017 and September 25, 2016 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive income (loss) before reclassifications 3,383 (1,050 ) 156,012 158,345 Amounts reclassified from accumulated other comprehensive income 1,535 3,387 — 4,922 Net current-period other comprehensive income 4,918 2,337 156,012 163,267 Balance as of October 1, 2017 $ 2,494 $ (134,259 ) $ (143,685 ) $ (275,450 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2015 $ (2,491 ) $ (138,887 ) $ (229,746 ) $ (371,124 ) Other comprehensive (loss) before reclassifications (2,255 ) 618 11,131 9,494 Amounts reclassified from accumulated other comprehensive loss 3,016 3,296 — 6,312 Net current-period other comprehensive income 761 3,914 11,131 15,806 Reclassification related to acquisition of noncontrolling interest — — (832 ) (832 ) Balance at September 25, 2016 $ (1,730 ) $ (134,973 ) $ (219,447 ) $ (356,150 ) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and nine months ended October 1, 2017 and September 25, 2016 : Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (1,179 ) $ 535 $ 1,769 $ 3,907 Total before tax (1,179 ) 535 1,769 3,907 Taxes (benefit) 237 (187 ) (234 ) (891 ) Net of tax $ (942 ) $ 348 $ 1,535 $ 3,016 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,723 $ 1,829 $ 5,176 $ 5,071 Prior-service costs (1) 20 15 79 43 Total before tax 1,743 1,844 5,255 5,114 Tax benefit (619 ) (657 ) (1,868 ) (1,818 ) Net of tax $ 1,124 $ 1,187 $ 3,387 $ 3,296 Total reclassifications, net of tax $ 182 $ 1,535 $ 4,922 $ 6,312 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information). Mezzanine Equity As of December 31, 2016, the Company reclassified $1.8 million from additional paid-in capital to convertible notes in the mezzanine equity section of the Company's consolidated balance sheet. The reclassified amount represents the aggregate difference between the principal amount and the carrying value of the Convertible Notes purchased by the Company pursuant to the Exchange Transactions (see "3.875% Convertible Senior Subordinated Notes - Exchange Transactions" within Note 7) under agreements that were entered into prior to December 31,2016, but not consummated until January 5, 2017 . No reclassification was required as of October 1, 2017 .

Taxes on income from continuing

Taxes on income from continuing operations	9 Months Ended
	Oct. 01, 2017
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Note 11 — Taxes on income from continuing operations Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 Effective income tax rate 11.2% 10.2% 8.9% 9.3% The effective income tax rate for the three and nine months ended October 1, 2017 was 11.2% and 8.9% , respectively, and 10.2% and 9.3% for the three and nine months ended September 25, 2016 , respectively. The effective income tax rate for the three months ended October 1, 2017, as compared to the prior year period, reflects a tax cost associated with an increase in the estimated deferred tax with respect to non-permanently reinvested income .

Pension and other postretiremen

Pension and other postretirement benefits	9 Months Ended
	Oct. 01, 2017
Compensation and Retirement Disclosure [Abstract]
Pension and other postretirement benefits	Note 12 — Pension and other postretirement benefits The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of October 1, 2017 , no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) Service cost $ 725 $ 656 $ 61 $ 44 $ 2,162 $ 1,963 $ 210 $ 266 Interest cost 3,773 3,948 426 383 11,347 11,797 1,183 1,196 Expected return on plan assets (6,607 ) (6,209 ) — — (20,100 ) (18,606 ) — — Net amortization and deferral 1,668 1,781 75 63 5,049 4,937 206 177 Net benefits expense (income) $ (441 ) $ 176 $ 562 $ 490 $ (1,542 ) $ 91 $ 1,599 $ 1,639

Commitments and contingent liab

Commitments and contingent liabilities	9 Months Ended
	Oct. 01, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Note 13 — Commitments and contingent liabilities Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At October 1, 2017 , the Company has recorded $1.1 million and $5.8 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of October 1, 2017 . The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15 - 20 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment, environmental and other matters. As of October 1, 2017 , the Company has recorded accrued liabilities of $8.6 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Of the amount accrued as of October 1, 2017 , $5.0 million pertains to discontinued operations. During the first quarter 2017, Teleflex Medical Trading (Shanghai) Company, Ltd. (“Teleflex Shanghai”), one of the Company’s subsidiaries, eliminated a key distributor within its sales channel in China and undertook a distributor to direct sales conversion within that channel. On March 24, 2017, the distributor submitted an application with the Shanghai International Economy and Trade Arbitration Commission (“SHIAC”) for arbitration alleging, among other things, that Teleflex Shanghai wrongfully terminated its relationship with the distributor. Pursuant to a supplementary submission filed by the distributor with SHIAC in July 2017, the distributor is seeking to recover RMB 51.2 million ( $7.5 million ) in damages, and is also seeking to compel Teleflex Shanghai to repurchase Teleflex products that the distributor claims it purchased from Teleflex Shanghai at a total price of RMB 97.5 million ( $14.4 million ). Teleflex Shanghai has filed a counterclaim seeking payment from the distributor of RMB 61.2 million ( $9.0 million ) in respect of outstanding trade receivables owed by the distributor to Teleflex Shanghai. Although the parties are exploring settlement of the claims, Teleflex Shanghai continues to vigorously contest the distributor's claim for damages. The Company has accrued a liability representing its best estimate of probable loss associated with this matter, which is included in the Company’s accrued liabilities for litigation matters. In 2006, the Company was named as a defendant in a wrongful death product liability lawsuit filed in the Louisiana State District Court for the Parish of Calcasieu, involving a product manufactured by the Company’s former marine business. In September 2014, the case was tried before a jury, which returned a verdict in favor of the Company. The plaintiff subsequently filed a motion for a new trial, which was granted, and the case was re-tried before a jury in December 2014. On December 5, 2014, the jury returned a verdict in favor of the plaintiff, awarding $0.1 million in compensatory damages and $23.0 million in punitive damages, plus pre- and post-judgment interest on the compensatory damages and post-judgment interest on the punitive damages. The Company filed an appeal with the Louisiana Court of Appeal, and the plaintiff filed a cross-appeal, seeking to overturn the trial court’s denial of pre-judgment interest on the punitive damages award. On June 29, 2016, the Louisiana Court of Appeal affirmed the trial court verdict in all respects. The Company and the plaintiff filed applications for a writ of certiorari (a request for review) to the Louisiana Supreme Court. On January 13, 2017, the Louisiana Supreme Court granted the Company's writ application, and oral arguments were held on May 1, 2017. On October 18, 2017, the Louisiana Supreme Court issued its decision, affirming the lower court’s judgment in part and reducing the amount of punitive damages awarded to the plaintiff from $23.0 million to $4.3 million . On November 1, 2017, the Company filed an application for a rehearing before the Louisiana Supreme Court. As of October 1, 2017 , the Company has accrued a $5.0 million liability, including punitive and compensatory damages as well as interest, representing its best estimate of probable loss associated with this matter, which is included in the Company’s accrued liabilities for litigation matters relating to discontinued operations. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of October 1, 2017 , the most significant tax examinations in process are in Canada, Germany and the United States. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts its reserves to address developments with respect to these uncertain tax positions. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results. Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Segment information

Segment information	9 Months Ended
	Oct. 01, 2017
Segment Reporting [Abstract]
Segment information	Note 14 — Segment information The following tables present the Company’s segment results for the three and nine months ended October 1, 2017 and September 25, 2016 : Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Dollars in thousands) Revenue Vascular North America $ 90,979 $ 85,118 $ 278,350 $ 254,817 Anesthesia North America 50,819 48,670 148,107 143,821 Surgical North America 40,804 41,827 131,464 123,904 EMEA 131,517 121,398 394,212 375,198 Asia 72,387 64,087 185,328 176,434 OEM 48,589 41,418 137,067 115,693 All other 99,608 53,130 276,669 164,227 Consolidated net revenues $ 534,703 $ 455,648 $ 1,551,197 $ 1,354,094 Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Dollars in thousands) Operating profit Vascular North America $ 25,212 $ 21,781 $ 75,286 $ 63,431 Anesthesia North America 15,684 13,954 49,727 41,181 Surgical North America 13,618 14,050 47,285 39,654 EMEA 24,187 16,576 69,677 61,563 Asia 20,217 18,072 49,619 52,831 OEM 12,256 10,201 31,714 24,605 All other 11,987 3,444 16,953 16,623 Total segment operating profit (1) 123,161 98,078 340,261 299,888 Unallocated expenses (2) (12,807 ) (11,591 ) (58,886 ) (47,463 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 110,354 $ 86,487 $ 281,375 $ 252,425 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guarant

Condensed consolidating guarantor financial information	9 Months Ended
	Oct. 01, 2017
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Note 15 — Condensed consolidating guarantor financial information Teleflex Incorporated (the "Parent Company") is the issuer of its 5.25% Senior Notes due 2024 (the "2024 Notes") and 4.875% Senior Notes due 2026 (the "2026 Notes"). Payment of the Parent Company's obligations under the 2024 Notes and 2026 Notes is guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three and nine months ended October 1, 2017 and September 25, 2016 , condensed consolidating balance sheets as of October 1, 2017 and December 31, 2016 and condensed consolidating statements of cash flows for the nine months ended October 1, 2017 and September 25, 2016 , provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the 2024 Notes and 2026 Notes), on a combined basis; and d. Parent Company and its subsidiaries on a consolidated basis. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 335,051 $ 303,676 $ (104,024 ) $ 534,703 Cost of goods sold — 194,262 149,302 (104,088 ) 239,476 Gross profit — 140,789 154,374 64 295,227 Selling, general and administrative expenses 10,536 89,315 64,046 (126 ) 163,771 Research and development expenses 220 14,788 6,186 — 21,194 Restructuring charges (credits) — 552 (644 ) — (92 ) (Loss) income from continuing operations before interest and taxes (10,756 ) 36,134 84,786 190 110,354 Interest, net 53,521 (33,392 ) 849 — 20,978 (Loss) income from continuing operations before taxes (64,277 ) 69,526 83,937 190 89,376 (Benefit) taxes on (loss) income from continuing operations (30,845 ) 23,453 17,364 6 9,978 Equity in net income of consolidated subsidiaries 112,830 61,027 257 (174,114 ) — Income from continuing operations 79,398 107,100 66,830 (173,930 ) 79,398 Operating loss from discontinued operations (3,749 ) — — — (3,749 ) Benefit on loss from discontinued operations (1,366 ) — — — (1,366 ) Loss from discontinued operations (2,383 ) — — — (2,383 ) Net income 77,015 107,100 66,830 (173,930 ) 77,015 Other comprehensive income 43,845 30,196 56,286 (86,482 ) 43,845 Comprehensive income $ 120,860 $ 137,296 $ 123,116 $ (260,412 ) $ 120,860 Three Months Ended September 25, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 270,610 $ 281,258 $ (96,220 ) $ 455,648 Cost of goods sold — 163,052 147,240 (96,246 ) 214,046 Gross profit — 107,558 134,018 26 241,602 Selling, general and administrative expenses 11,208 80,333 48,285 (29 ) 139,797 Research and development expenses 179 8,422 6,466 — 15,067 Restructuring charges 380 1,712 935 — 3,027 (Gain) loss on sale of assets (2,707 ) 104 (173 ) — (2,776 ) (Loss) income from continuing operations before interest and taxes (9,060 ) 16,987 78,505 55 86,487 Interest, net 41,344 (29,612 ) 1,041 — 12,773 (Loss) income from continuing operations before taxes (50,404 ) 46,599 77,464 55 73,714 (Benefit) taxes on (loss) income from continuing operations (18,017 ) 13,166 12,437 (72 ) 7,514 Equity in net income of consolidated subsidiaries 98,544 57,837 183 (156,564 ) — Income from continuing operations 66,157 91,270 65,210 (156,437 ) 66,200 Operating income from discontinued operations 260 — — — 260 Taxes on income from discontinued operations 95 — 43 — 138 Income (loss) from discontinued operations 165 — (43 ) — 122 Net income attributable to common shareholders 66,322 91,270 65,167 (156,437 ) 66,322 Other comprehensive income (loss) attributable to common shareholders 1,053 (501 ) 1,243 (742 ) 1,053 Comprehensive income attributable to common shareholders $ 67,375 $ 90,769 $ 66,410 $ (157,179 ) $ 67,375 Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 989,314 $ 876,968 $ (315,085 ) $ 1,551,197 Cost of goods sold — 576,465 445,638 (311,977 ) 710,126 Gross profit — 412,849 431,330 (3,108 ) 841,071 Selling, general and administrative expenses 38,523 278,529 169,224 398 486,674 Research and development expenses 719 39,568 19,012 — 59,299 Restructuring charges — 7,261 6,462 — 13,723 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (39,242 ) 87,491 236,632 (3,506 ) 281,375 Interest, net 152,268 (96,776 ) 2,776 — 58,268 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (197,103 ) 184,267 233,856 (3,506 ) 217,514 (Benefit) taxes on (loss) income from continuing operations (83,867 ) 60,061 43,803 (593 ) 19,404 Equity in net income of consolidated subsidiaries 311,346 175,690 713 (487,749 ) — Income from continuing operations 198,110 299,896 190,766 (490,662 ) 198,110 Operating loss from discontinued operations (4,597 ) — — — (4,597 ) Benefit on loss from discontinued operations (1,675 ) — — — (1,675 ) Loss from discontinued operations (2,922 ) — — — (2,922 ) Net income 195,188 299,896 190,766 (490,662 ) 195,188 Other comprehensive income 163,267 147,727 179,561 (327,288 ) 163,267 Comprehensive income $ 358,455 $ 447,623 $ 370,327 $ (817,950 ) $ 358,455 Nine Months Ended September 25, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 809,951 $ 833,390 $ (289,247 ) $ 1,354,094 Cost of goods sold — 489,293 427,200 (285,547 ) 630,946 Gross profit — 320,658 406,190 (3,700 ) 723,148 Selling, general and administrative expenses 30,822 248,195 139,641 470 419,128 Research and development expenses 319 23,501 19,072 — 42,892 Restructuring charges 380 7,027 5,469 — 12,876 Gain on sale of assets (2,707 ) (274 ) (1,192 ) — (4,173 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (28,814 ) 42,209 243,200 (4,170 ) 252,425 Interest, net 107,534 (72,367 ) 3,088 — 38,255 Loss on extinguishment of debt 19,261 — — — 19,261 (Loss) income from continuing operations before taxes (155,609 ) 114,576 240,112 (4,170 ) 194,909 (Benefit) taxes on (loss) income from continuing operations (56,942 ) 39,347 36,210 (481 ) 18,134 Equity in net income of consolidated subsidiaries 275,296 179,342 526 (455,164 ) — Income from continuing operations 176,629 254,571 204,428 (458,853 ) 176,775 Operating (loss) income from discontinued operations (495 ) — 379 — (116 ) (Benefit) taxes on (loss) income from discontinued operations (180 ) — 61 — (119 ) (Loss) income from discontinued operations (315 ) — 318 — 3 Net income 176,314 254,571 204,746 (458,853 ) 176,778 Less: Income from continuing operations attributable to noncontrolling interest — — 464 — 464 Net income attributable to common shareholders 176,314 254,571 204,282 (458,853 ) 176,314 Other comprehensive income attributable to common shareholders 15,806 8,387 12,277 (20,664 ) 15,806 Comprehensive income attributable to common shareholders $ 192,120 $ 262,958 $ 216,559 $ (479,517 ) $ 192,120 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 45,189 $ 748,412 $ 223,972 $ — $ 1,017,573 Accounts receivable, net 2,232 36,055 263,725 4,460 306,472 Accounts receivable from consolidated subsidiaries 9,095 2,273,240 359,560 (2,641,895 ) — Inventories, net — 236,355 174,561 (28,499 ) 382,417 Prepaid expenses and other current assets 15,492 8,722 24,048 3,337 51,599 Prepaid taxes — — 8,690 — 8,690 Total current assets 72,008 3,302,784 1,054,556 (2,662,597 ) 1,766,751 Property, plant and equipment, net 2,247 209,966 162,248 — 374,461 Goodwill — 902,429 983,728 — 1,886,157 Intangibles assets, net — 612,745 994,198 — 1,606,943 Investments in consolidated subsidiaries 7,245,740 1,801,602 23,546 (9,070,888 ) — Deferred tax assets — — 5,496 (3,476 ) 2,020 Notes receivable and other amounts due from consolidated subsidiaries 2,082,206 2,256,368 — (4,338,574 ) — Other assets 29,378 6,308 8,715 — 44,401 Total assets $ 9,431,579 $ 9,092,202 $ 3,232,487 $ (16,075,535 ) $ 5,680,733 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 27,250 $ — $ 50,000 $ — $ 77,250 Accounts payable 2,343 47,014 36,062 — 85,419 Accounts payable to consolidated subsidiaries 2,307,797 275,465 58,633 (2,641,895 ) — Accrued expenses 20,127 24,398 43,570 — 88,095 Current portion of contingent consideration — 591 — — 591 Payroll and benefit-related liabilities 19,973 28,011 40,107 — 88,091 Accrued interest 13,402 — 28 — 13,430 Income taxes payable 2,168 — 11,282 (593 ) 12,857 Other current liabilities 344 5,335 3,233 — 8,912 Total current liabilities 2,393,404 380,814 242,915 (2,642,488 ) 374,645 Long-term borrowings 2,172,805 — — — 2,172,805 Deferred tax liabilities 118,891 314,168 42,084 (3,476 ) 471,667 Pension and postretirement benefit liabilities 67,836 30,928 17,677 — 116,441 Noncurrent liability for uncertain tax positions 2,035 9,175 3,028 — 14,238 Notes payable and other amounts due to consolidated subsidiaries 2,178,181 1,954,051 206,342 (4,338,574 ) — Other liabilities 25,950 13,943 18,567 — 58,460 Total liabilities 6,959,102 2,703,079 530,613 (6,984,538 ) 3,208,256 Total shareholders' equity 2,472,477 6,389,123 2,701,874 (9,090,997 ) 2,472,477 Total liabilities and shareholders' equity $ 9,431,579 $ 9,092,202 $ 3,232,487 $ (16,075,535 ) $ 5,680,733 December 31, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 14,571 $ 1,031 $ 528,187 $ — $ 543,789 Accounts receivable, net 2,551 8,768 255,815 4,859 271,993 Accounts receivable from consolidated subsidiaries 4,861 2,176,059 309,149 (2,490,069 ) — Inventories, net — 200,852 140,406 (25,087 ) 316,171 Prepaid expenses and other current assets 14,239 5,332 17,474 3,337 40,382 Prepaid taxes — — 7,766 413 8,179 Assets held for sale — — 2,879 — 2,879 Total current assets 36,222 2,392,042 1,261,676 (2,506,547 ) 1,183,393 Property, plant and equipment, net 2,566 163,847 136,486 — 302,899 Goodwill — 708,546 568,174 — 1,276,720 Intangibles assets, net — 640,999 450,664 — 1,091,663 Investments in consolidated subsidiaries 6,022,042 1,519,031 23,685 (7,564,758 ) — Deferred tax assets 73,051 — 5,185 (76,524 ) 1,712 Notes receivable and other amounts due from consolidated subsidiaries 1,387,615 2,085,538 — (3,473,153 ) — Other assets 22,295 6,254 6,277 — 34,826 Total assets $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 133,071 $ — $ 50,000 $ — $ 183,071 Accounts payable 4,540 30,924 33,936 — 69,400 Accounts payable to consolidated subsidiaries 2,242,814 214,203 33,052 (2,490,069 ) — Accrued expenses 16,827 18,126 30,196 — 65,149 Current portion of contingent consideration — 587 — — 587 Payroll and benefit-related liabilities 20,610 26,672 35,397 — 82,679 Accrued interest 10,429 — 21 — 10,450 Income taxes payable 1,246 — 6,577 85 7,908 Other current liabilities 2,262 3,643 2,497 — 8,402 Total current liabilities 2,431,799 294,155 191,676 (2,489,984 ) 427,646 Long-term borrowings 850,252 — — — 850,252 Deferred tax liabilities — 316,526 31,375 (76,524 ) 271,377 Pension and postretirement benefit liabilities 85,645 31,561 15,856 — 133,062 Noncurrent liability for uncertain tax positions 1,169 13,684 2,667 — 17,520 Notes payable and other amounts due to consolidated subsidiaries 2,011,737 1,264,004 197,412 (3,473,153 ) — Other liabilities 23,848 15,695 12,472 — 52,015 Total liabilities 5,404,450 1,935,625 451,458 (6,039,661 ) 1,751,872 Convertible notes - redeemable equity component 1,824 — — — 1,824 Mezzanine equity 1,824 — — — 1,824 Total shareholders' equity 2,137,517 5,580,632 2,000,689 (7,581,321 ) 2,137,517 Total liabilities and shareholders' equity $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (156,643 ) $ 300,961 $ 237,308 $ (61,918 ) $ 319,708 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (233 ) (27,527 ) (26,217 ) — (53,977 ) Proceeds from sale of assets and investments 464,982 — 6,332 (464,982 ) 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (35,187 ) — (1,010,711 ) Net cash used in investing activities from continuing operations (510,775 ) (27,527 ) (55,072 ) (464,982 ) (1,058,356 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,963,500 — — — 1,963,500 Reduction in borrowings (747,576 ) — — — (747,576 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 4,739 — — — 4,739 Payments for contingent consideration — (245 ) — — (245 ) Dividends paid (45,905 ) — — — (45,905 ) Intercompany transactions (456,468 ) 474,192 (482,706 ) 464,982 — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 699,176 473,947 (544,624 ) 526,900 1,155,399 Cash flows from discontinued operations: Net cash used in operating activities (1,140 ) — — — (1,140 ) Net cash used in discontinued operations (1,140 ) — — — (1,140 ) Effect of exchange rate changes on cash and cash equivalents — — 58,173 — 58,173 Net increase in cash and cash equivalents 30,618 747,381 (304,215 ) — 473,784 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 45,189 $ 748,412 $ 223,972 $ — $ 1,017,573 Nine Months Ended September 25, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (72,542 ) $ 123,249 $ 253,166 $ (2,275 ) $ 301,598 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (191 ) (15,713 ) (20,008 ) — (35,912 ) Proceeds from sale of assets 5,607 49,571 1,451 (46,837 ) 9,792 Payments for businesses and intangibles acquired, net of cash acquired — (10,305 ) (50,572 ) 46,837 (14,040 ) Net cash (used in) provided by investing activities from continuing operations 5,416 23,553 (69,129 ) — (40,160 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 665,000 — 6,700 — 671,700 Reduction in borrowings (714,487 ) — — — (714,487 ) Debt extinguishment, issuance and amendment fees (8,958 ) — — — (8,958 ) Net proceeds from share based compensation plans and the related tax impacts 7,647 — — — 7,647 Payments to noncontrolling interest shareholders — — (464 ) — (464 ) Payments for contingent consideration — (133 ) — — (133 ) Payments for acquisition of noncontrolling interest — — (9,231 ) — (9,231 ) Dividends paid (43,980 ) — — — (43,980 ) Intercompany transactions 175,203 (145,645 ) (29,558 ) — — Intercompany dividends paid — — (2,275 ) 2,275 — Net cash provided by (used in) financing activities from continuing operations 80,425 (145,778 ) (34,828 ) 2,275 (97,906 ) Cash flows from discontinued operations: Net cash used in operating activities (1,451 ) — — — (1,451 ) Net cash used in discontinued operations (1,451 ) — — — (1,451 ) Effect of exchange rate changes on cash and cash equivalents — — (988 ) — (988 ) Net increase in cash and cash equivalents 11,848 1,024 148,221 — 161,093 Cash and cash equivalents at the beginning of the period 21,612 — 316,754 — 338,366 Cash and cash equivalents at the end of the period $ 33,460 $ 1,024 $ 464,975 $ — $ 499,459

Subsequent events (Notes)

Subsequent events (Notes)	9 Months Ended
	Oct. 01, 2017
Subsequent Events [Abstract]
Subsequent events	Note 16 — Subsequent event NeoTract Acquisition On October 2, 2017, the Company completed the acquisition of NeoTract, a privately-held company, pursuant to an Agreement and Plan of Merger, dated as of September 4, 2017. NeoTract is a medical device company that has developed and commercialized the UroLift® System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. Under the terms of the agreement, the Company acquired NeoTract for an initial purchase price $725 million in cash, subject to customary purchase price adjustments. In addition, the agreement also provides for four milestone payments by the Company of up to $375 million in the aggregate if certain sales goals are met. The milestone payments are based on net sales (as defined in the agreement) for the periods from January 1, 2018 through April 30, 2018 and the years ended December 31, 2018, 2019 and 2020. The acquisition was financed using borrowings under the Company's revolving credit facility.

New accounting standards (Polic

New accounting standards (Policies)	9 Months Ended
	Oct. 01, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, collectively with related guidance provided by the FASB, is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. The Company will adopt this standard in the first quarter 2018 and expects to use the modified retrospective method of adoption by recognizing the cumulative effect of adopting this guidance as an adjustment to the Company's opening balance of retained earnings at January 1, 2018. Although the Company's evaluation of this guidance is ongoing, based on its assessment to date, the Company believes that the adoption of this guidance will not have a material impact on its consolidated results of operations, cash flows and financial position. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including, among other things, guidance related to accounting for income taxes, modification of the criteria for classification of awards as either equity awards or liability awards where an employer withholds shares from an employee's share-based award for tax withholding purposes, and classification on the statement of cash flows of cash payments to a tax authority by an employer that withholds shares from an employee's award for tax withholding purposes. The Company adopted this guidance as of January 1, 2017. The Company has applied the new guidance requiring recognition of excess tax deficiencies and tax benefits in the income statement, rather than in additional paid-in-capital, as previously required. The adoption of the new standard increased net income and cash flows from operating activities by $1.5 million and $5.9 million and increased diluted earnings per share by $0.03 and $0.13 for the three and nine months ended October 1, 2017 , respectively. The Company will continue to estimate forfeitures of share-based awards at the time of grant, rather than recognize actual forfeitures as they occur, as permitted under the new guidance. In August 2016, the FASB issued new guidance with regard to eight specific issues pertaining to the classification of certain cash receipts and cash payments within the statement of cash flows. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. The new guidance should generally be adopted using a retrospective transition method for each period presented. The Company believes that its adoption of the new guidance will not have a material impact on its cash flows. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. The Company is evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued new guidance to clarify the definition of a “business,” with the objective of assisting entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or as an acquisition of a business. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill and consolidation. The guidance generally defines a business as an integrated set of activities and assets (collectively referred to as a “set”) that is capable of being conducted and managed for the purpose of providing a return to investors or other owners, members, or participants. The guidance further provides that, to be considered a business, a set must meet specified requirements. However, the guidance also states that, if substantially all of the fair value of gross assets acquired (subject to specified exceptions) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and no further analysis is required. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance permits early adoption, and the Company adopted this guidance during the fourth quarter 2017. The Company does not anticipate that the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued guidance to simplify the quantitative test for goodwill impairment. Under current guidance, if a reporting unit’s carrying value exceeds its fair value, the entity must determine the implied value of goodwill. This determination is made by deducting the fair value of a reporting unit’s identifiable assets and liabilities from the fair value of the reporting unit as a whole as if the reporting unit had just been acquired. Under the new guidance, a determination of the implied value of goodwill will no longer be required; a goodwill impairment will be equal to the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The revised guidance is effective for fiscal years, and any interim goodwill impairment tests within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated results of operations and financial position. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Oct. 01, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the purchase price allocation among the assets acquired and liabilities assumed with respect to the Vascular Solutions acquisition: (Dollars in thousands) Assets Current assets $ 63,867 Property, plant and equipment 46,616 Intangible assets 539,250 Goodwill 522,614 Other assets 728 Total assets acquired 1,173,075 Less: Current liabilities 15,079 Deferred tax liabilities 182,472 Liabilities assumed 197,551 Net assets acquired $ 975,524
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of the Vascular Solutions acquisition: Fair value Useful life range (Dollars in thousands) (Years) Intellectual property 248,200 10- 20 In-process research and development ("IPR&D") 15,600 Indefinite Trade names 16,650 20 Customer lists 258,800 25
Business Acquisition, Pro Forma Information	The following unaudited pro forma combined financial information for the three and nine months ended October 1, 2017 and September 25, 2016 , respectively, gives effect to the Vascular Solutions acquisition as if it was completed at the beginning of the earliest period presented. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars and shares in thousands, except per share) Net revenue $ 534,703 $ 497,253 $ 1,574,021 $ 1,475,950 Net income $ 76,194 $ 63,578 $ 209,630 $ 136,493 Basic earnings per common share: Net income $ 1.69 $ 1.44 $ 4.66 $ 3.17 Diluted earnings per common share: Net income $ 1.64 $ 1.34 $ 4.49 $ 2.85 Weighted average common shares outstanding: Basic 45,035 44,045 44,975 43,081 Diluted 46,587 47,446 46,673 47,824

Restructuring (credits) charg27

Restructuring (credits) charges (Tables)	9 Months Ended
	Oct. 01, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Other Impairment Charges	The following tables provide information regarding restructuring (credits) charges recognized by the Company for the three and nine months ended October 1, 2017 and September 25, 2016 : Three Months Ended October 1, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ (319 ) $ — $ — $ 58 $ (261 ) 2017 EMEA restructuring program (714 ) — — 84 (630 ) 2016 Footprint realignment plan 274 72 — 85 431 2014 Footprint realignment plan 197 46 — 6 249 Other restructuring programs (1) 8 — 104 7 119 Total restructuring (credits) charges $ (554 ) $ 118 $ 104 $ 240 $ (92 ) Three Months Ended September 25, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Other Restructuring programs $ 1,713 $ — $ — $ — $ 1,713 2016 Footprint realignment plan 851 — — 74 925 2014 Footprint realignment plan 308 — — 6 314 Other restructuring programs (2) (88 ) 54 107 2 75 Total restructuring charges $ 2,784 $ 54 $ 107 $ 82 $ 3,027 Nine Months Ended October 1, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 4,534 $ — $ — $ 92 $ 4,626 2017 EMEA restructuring program 5,822 — — 84 5,906 2016 Footprint realignment plan 1,099 94 (75 ) 214 1,332 2014 Footprint realignment plan 379 60 — 7 446 Other restructuring programs (3) 973 58 313 69 1,413 Total restructuring charges $ 12,807 $ 212 $ 238 $ 466 $ 13,723 Nine Months Ended September 25, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Other Restructuring programs $ 1,713 $ — $ — $ — $ 1,713 2016 Footprint realignment plan 10,919 — — 360 11,279 2014 Footprint realignment plan (118 ) — — 17 (101 ) Other restructuring programs (4) (487 ) $ 232 $ 114 126 (15 ) Total restructuring charges $ 12,027 $ 232 $ 114 $ 503 $ 12,876 (1) Other restructuring programs include the 2017 Pyng Integration program and the 2016 Other Restructuring programs. The Company committed to the 2017 Pyng Integration program, which relates to the integration of Pyng into Teleflex, during the second quarter 2017. (2) Other restructuring programs include the 2015 Restructuring programs and the 2014 European Restructuring Plan. (3) Other restructuring programs include the 2017 Pyng Integration program, the 2016 Other Restructuring programs, the 2015 Restructuring programs and the 2014 European Restructuring plan. (4) Other restructuring programs include the 2014 European Restructuring Plan and the 2012 Restructuring program. Restructuring (credits) charges by reportable operating segment, and by all other operating segments in the aggregate, for the three and nine months ended October 1, 2017 and September 25, 2016 are set forth in the following table: Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Dollars in thousands) Restructuring (credits) charges Vascular North America $ 606 $ 960 $ 1,715 $ 5,474 Anesthesia North America 220 946 1,031 3,185 Surgical North America — 277 — 257 EMEA (632 ) 89 6,503 3,012 OEM — 187 — 191 All other (286 ) 568 4,474 757 Total restructuring (credits) charges $ (92 ) $ 3,027 $ 13,723 $ 12,876

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Oct. 01, 2017
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of October 1, 2017 and December 31, 2016 consisted of the following: October 1, 2017 December 31, 2016 (Dollars in thousands) Raw materials $ 98,322 $ 65,319 Work-in-process 60,020 54,555 Finished goods 224,075 196,297 Inventories, net $ 382,417 $ 316,171

Goodwill and other intangible29

Goodwill and other intangible assets, net (Tables)	9 Months Ended
	Oct. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the nine months ended October 1, 2017 : Vascular Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) Balance as of December 31, 2016 $ 345,546 $ 141,253 $ 250,912 $ 290,041 $ 138,185 $ 4,883 $ 105,900 $ 1,276,720 Goodwill related to acquisitions — 15,594 — 9,139 2,927 — 522,614 550,274 Currency translation and other adjustments (1,590 ) 458 — 33,665 8,585 — 18,045 59,163 Balance as of October 1, 2017 $ 343,956 $ 157,305 $ 250,912 $ 332,845 $ 149,697 $ 4,883 $ 646,559 $ 1,886,157
Schedule of Finite-Lived Intangible Assets	The following table provides information as of October 1, 2017 and December 31, 2016 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets: Gross Carrying Amount Accumulated Amortization October 1, 2017 December 31, 2016 October 1, 2017 December 31, 2016 (Dollars in thousands) Customer relationships $ 901,367 $ 622,428 $ (269,447 ) $ (239,055 ) In-process research and development 34,296 16,532 — — Intellectual property 778,292 519,962 (238,236 ) (203,390 ) Distribution rights 23,637 23,021 (16,663 ) (15,239 ) Trade names 408,362 379,724 (18,343 ) (13,974 ) Non-compete agreements 5,354 2,692 (1,676 ) (1,038 ) $ 2,151,308 $ 1,564,359 $ (544,365 ) $ (472,696 )

Borrowings (Tables)

Borrowings (Tables)	9 Months Ended
	Oct. 01, 2017
Debt Disclosure [Abstract]
Components of Long-Term Debt	The Company's borrowings at October 1, 2017 and December 31, 2016 were as follows: October 1, 2017 December 31, 2016 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 3.24% at October 1, 2017, due 2022 $ 841,000 $ 210,000 Term loan facility, at a rate of 3.24% at October 1, 2017, due 2022 721,000 — 3.875% Convertible Senior Subordinated Notes due 2017 — 136,076 4.875% Senior Notes due 2026 400,000 400,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 1.98% at October 1, 2017 50,000 50,000 2,262,000 1,046,076 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 — (2,707 ) Less: Unamortized debt issuance costs (11,945 ) (10,046 ) 2,250,055 1,033,323 Current borrowings (77,250 ) (183,071 ) Long-term borrowings $ 2,172,805 $ 850,252
Fair Value of Long-Term Debt	The following table provides information regarding the fair value of the Company’s debt as of October 1, 2017 and December 31, 2016 , categorized by the level of inputs within the fair value hierarchy used to measure fair value: October 1, 2017 December 31, 2016 (Dollars in thousands) Level 1 $ — $ 344,765 Level 2 2,254,376 929,362 Total $ 2,254,376 $ 1,274,127

Financial instruments (Tables)

Financial instruments (Tables)	9 Months Ended
	Oct. 01, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of October 1, 2017 and December 31, 2016 : October 1, 2017 December 31, 2016 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 1,684 $ 667 Non-designated foreign currency forward contracts 318 490 Prepaid expenses and other current assets $ 2,002 $ 1,157 Total asset derivatives $ 2,002 $ 1,157 Liability derivatives: Designated foreign currency forward contracts $ 237 $ 2,139 Non-designated foreign currency forward contracts 93 118 Other current liabilities $ 330 $ 2,257 Total liability derivatives $ 330 $ 2,257
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at October 1, 2017 and December 31, 2016 : October 1, 2017 December 31, 2016 (Dollars in thousands) Allowance for doubtful accounts (1) $ 10,084 $ 8,630 Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal (2) $ 50,613 $ 51,098 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 16.9 % 19.3 % (1) The current portion of the allowance for doubtful accounts was $3.1 million and $2.0 million as of October 1, 2017 and December 31, 2016 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at October 1, 2017 and December 31, 2016 was $3.5 million and $2.7 million , respectively. In January 2017, the Company sold $16.1 million of receivables outstanding with respect to publicly funded hospitals in Italy for $16.0 million .

Fair value measurement (Tables)

Fair value measurement (Tables)	9 Months Ended
	Oct. 01, 2017
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of October 1, 2017 and December 31, 2016 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,563 $ 8,563 $ — $ — Derivative assets 2,002 — 2,002 — Derivative liabilities 330 — 330 — Contingent consideration liabilities (1) 12,117 — — 12,117 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 7,660 $ 7,660 $ — $ — Derivative assets 1,157 — 1,157 — Derivative liabilities 2,257 — 2,257 — Contingent consideration liabilities (1) 7,102 — — 7,102 (1) As of October 1, 2017 and December 31, 2016, (a) $0.6 million of contingent consideration liabilities were recognized in the current portion of contingent consideration, and (b) $11.5 million and $6.5 million of contingent consideration liabilities, respectively, were recognized in other liabilities in the condensed consolidated balance sheet.
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes, during the nine months ended October 1, 2017 , in Level 3 financial liabilities related to contingent consideration, which are described below in this Note 9 under "Valuation Techniques": Contingent consideration 2017 (Dollars in thousands) Balance - December 31, 2016 $ 7,102 Additions (1) 5,369 Payment (245 ) Revaluations (109 ) Balance - October 1, 2017 $ 12,117 (1) The Company established a liability related to the estimated fair value of contingent consideration associated with the Tianjin Medis acquisition.

Shareholders' equity (Tables)

Shareholders' equity (Tables)	9 Months Ended
	Oct. 01, 2017
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Shares in thousands) Basic 45,035 44,045 44,975 43,081 Dilutive effect of share-based awards 934 639 873 574 Dilutive effect of 3.875% Convertible Notes and warrants (1) 618 2,762 825 4,169 Diluted 46,587 47,446 46,673 47,824 (1) The reduction in the dilutive effect of the Convertible Notes and warrants during the three and nine months ended October 1, 2017 as compared to three and nine months ended September 25, 2016 is due principally to the Company’s repurchase of Convertible Notes and conversions by holders of the Convertible Notes.
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended October 1, 2017 and September 25, 2016 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive income (loss) before reclassifications 3,383 (1,050 ) 156,012 158,345 Amounts reclassified from accumulated other comprehensive income 1,535 3,387 — 4,922 Net current-period other comprehensive income 4,918 2,337 156,012 163,267 Balance as of October 1, 2017 $ 2,494 $ (134,259 ) $ (143,685 ) $ (275,450 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2015 $ (2,491 ) $ (138,887 ) $ (229,746 ) $ (371,124 ) Other comprehensive (loss) before reclassifications (2,255 ) 618 11,131 9,494 Amounts reclassified from accumulated other comprehensive loss 3,016 3,296 — 6,312 Net current-period other comprehensive income 761 3,914 11,131 15,806 Reclassification related to acquisition of noncontrolling interest — — (832 ) (832 ) Balance at September 25, 2016 $ (1,730 ) $ (134,973 ) $ (219,447 ) $ (356,150 )
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and nine months ended October 1, 2017 and September 25, 2016 : Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (1,179 ) $ 535 $ 1,769 $ 3,907 Total before tax (1,179 ) 535 1,769 3,907 Taxes (benefit) 237 (187 ) (234 ) (891 ) Net of tax $ (942 ) $ 348 $ 1,535 $ 3,016 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,723 $ 1,829 $ 5,176 $ 5,071 Prior-service costs (1) 20 15 79 43 Total before tax 1,743 1,844 5,255 5,114 Tax benefit (619 ) (657 ) (1,868 ) (1,818 ) Net of tax $ 1,124 $ 1,187 $ 3,387 $ 3,296 Total reclassifications, net of tax $ 182 $ 1,535 $ 4,922 $ 6,312 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui34

Taxes on income from continuing operations (Tables)	9 Months Ended
	Oct. 01, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 Effective income tax rate 11.2% 10.2% 8.9% 9.3%

Pension and other postretirem35

Pension and other postretirement benefits (Tables)	9 Months Ended
	Oct. 01, 2017
Compensation and Retirement Disclosure [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) Service cost $ 725 $ 656 $ 61 $ 44 $ 2,162 $ 1,963 $ 210 $ 266 Interest cost 3,773 3,948 426 383 11,347 11,797 1,183 1,196 Expected return on plan assets (6,607 ) (6,209 ) — — (20,100 ) (18,606 ) — — Net amortization and deferral 1,668 1,781 75 63 5,049 4,937 206 177 Net benefits expense (income) $ (441 ) $ 176 $ 562 $ 490 $ (1,542 ) $ 91 $ 1,599 $ 1,639

Segment information (Tables)

Segment information (Tables)	9 Months Ended
	Oct. 01, 2017
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three and nine months ended October 1, 2017 and September 25, 2016 : Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Dollars in thousands) Revenue Vascular North America $ 90,979 $ 85,118 $ 278,350 $ 254,817 Anesthesia North America 50,819 48,670 148,107 143,821 Surgical North America 40,804 41,827 131,464 123,904 EMEA 131,517 121,398 394,212 375,198 Asia 72,387 64,087 185,328 176,434 OEM 48,589 41,418 137,067 115,693 All other 99,608 53,130 276,669 164,227 Consolidated net revenues $ 534,703 $ 455,648 $ 1,551,197 $ 1,354,094 Three Months Ended Nine Months Ended October 1, 2017 September 25, 2016 October 1, 2017 September 25, 2016 (Dollars in thousands) (Dollars in thousands) Operating profit Vascular North America $ 25,212 $ 21,781 $ 75,286 $ 63,431 Anesthesia North America 15,684 13,954 49,727 41,181 Surgical North America 13,618 14,050 47,285 39,654 EMEA 24,187 16,576 69,677 61,563 Asia 20,217 18,072 49,619 52,831 OEM 12,256 10,201 31,714 24,605 All other 11,987 3,444 16,953 16,623 Total segment operating profit (1) 123,161 98,078 340,261 299,888 Unallocated expenses (2) (12,807 ) (11,591 ) (58,886 ) (47,463 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 110,354 $ 86,487 $ 281,375 $ 252,425 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guara37

Condensed consolidating guarantor financial information (Tables)	9 Months Ended
	Oct. 01, 2017
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 335,051 $ 303,676 $ (104,024 ) $ 534,703 Cost of goods sold — 194,262 149,302 (104,088 ) 239,476 Gross profit — 140,789 154,374 64 295,227 Selling, general and administrative expenses 10,536 89,315 64,046 (126 ) 163,771 Research and development expenses 220 14,788 6,186 — 21,194 Restructuring charges (credits) — 552 (644 ) — (92 ) (Loss) income from continuing operations before interest and taxes (10,756 ) 36,134 84,786 190 110,354 Interest, net 53,521 (33,392 ) 849 — 20,978 (Loss) income from continuing operations before taxes (64,277 ) 69,526 83,937 190 89,376 (Benefit) taxes on (loss) income from continuing operations (30,845 ) 23,453 17,364 6 9,978 Equity in net income of consolidated subsidiaries 112,830 61,027 257 (174,114 ) — Income from continuing operations 79,398 107,100 66,830 (173,930 ) 79,398 Operating loss from discontinued operations (3,749 ) — — — (3,749 ) Benefit on loss from discontinued operations (1,366 ) — — — (1,366 ) Loss from discontinued operations (2,383 ) — — — (2,383 ) Net income 77,015 107,100 66,830 (173,930 ) 77,015 Other comprehensive income 43,845 30,196 56,286 (86,482 ) 43,845 Comprehensive income $ 120,860 $ 137,296 $ 123,116 $ (260,412 ) $ 120,860 Three Months Ended September 25, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 270,610 $ 281,258 $ (96,220 ) $ 455,648 Cost of goods sold — 163,052 147,240 (96,246 ) 214,046 Gross profit — 107,558 134,018 26 241,602 Selling, general and administrative expenses 11,208 80,333 48,285 (29 ) 139,797 Research and development expenses 179 8,422 6,466 — 15,067 Restructuring charges 380 1,712 935 — 3,027 (Gain) loss on sale of assets (2,707 ) 104 (173 ) — (2,776 ) (Loss) income from continuing operations before interest and taxes (9,060 ) 16,987 78,505 55 86,487 Interest, net 41,344 (29,612 ) 1,041 — 12,773 (Loss) income from continuing operations before taxes (50,404 ) 46,599 77,464 55 73,714 (Benefit) taxes on (loss) income from continuing operations (18,017 ) 13,166 12,437 (72 ) 7,514 Equity in net income of consolidated subsidiaries 98,544 57,837 183 (156,564 ) — Income from continuing operations 66,157 91,270 65,210 (156,437 ) 66,200 Operating income from discontinued operations 260 — — — 260 Taxes on income from discontinued operations 95 — 43 — 138 Income (loss) from discontinued operations 165 — (43 ) — 122 Net income attributable to common shareholders 66,322 91,270 65,167 (156,437 ) 66,322 Other comprehensive income (loss) attributable to common shareholders 1,053 (501 ) 1,243 (742 ) 1,053 Comprehensive income attributable to common shareholders $ 67,375 $ 90,769 $ 66,410 $ (157,179 ) $ 67,375 Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 989,314 $ 876,968 $ (315,085 ) $ 1,551,197 Cost of goods sold — 576,465 445,638 (311,977 ) 710,126 Gross profit — 412,849 431,330 (3,108 ) 841,071 Selling, general and administrative expenses 38,523 278,529 169,224 398 486,674 Research and development expenses 719 39,568 19,012 — 59,299 Restructuring charges — 7,261 6,462 — 13,723 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (39,242 ) 87,491 236,632 (3,506 ) 281,375 Interest, net 152,268 (96,776 ) 2,776 — 58,268 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (197,103 ) 184,267 233,856 (3,506 ) 217,514 (Benefit) taxes on (loss) income from continuing operations (83,867 ) 60,061 43,803 (593 ) 19,404 Equity in net income of consolidated subsidiaries 311,346 175,690 713 (487,749 ) — Income from continuing operations 198,110 299,896 190,766 (490,662 ) 198,110 Operating loss from discontinued operations (4,597 ) — — — (4,597 ) Benefit on loss from discontinued operations (1,675 ) — — — (1,675 ) Loss from discontinued operations (2,922 ) — — — (2,922 ) Net income 195,188 299,896 190,766 (490,662 ) 195,188 Other comprehensive income 163,267 147,727 179,561 (327,288 ) 163,267 Comprehensive income $ 358,455 $ 447,623 $ 370,327 $ (817,950 ) $ 358,455 Nine Months Ended September 25, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 809,951 $ 833,390 $ (289,247 ) $ 1,354,094 Cost of goods sold — 489,293 427,200 (285,547 ) 630,946 Gross profit — 320,658 406,190 (3,700 ) 723,148 Selling, general and administrative expenses 30,822 248,195 139,641 470 419,128 Research and development expenses 319 23,501 19,072 — 42,892 Restructuring charges 380 7,027 5,469 — 12,876 Gain on sale of assets (2,707 ) (274 ) (1,192 ) — (4,173 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (28,814 ) 42,209 243,200 (4,170 ) 252,425 Interest, net 107,534 (72,367 ) 3,088 — 38,255 Loss on extinguishment of debt 19,261 — — — 19,261 (Loss) income from continuing operations before taxes (155,609 ) 114,576 240,112 (4,170 ) 194,909 (Benefit) taxes on (loss) income from continuing operations (56,942 ) 39,347 36,210 (481 ) 18,134 Equity in net income of consolidated subsidiaries 275,296 179,342 526 (455,164 ) — Income from continuing operations 176,629 254,571 204,428 (458,853 ) 176,775 Operating (loss) income from discontinued operations (495 ) — 379 — (116 ) (Benefit) taxes on (loss) income from discontinued operations (180 ) — 61 — (119 ) (Loss) income from discontinued operations (315 ) — 318 — 3 Net income 176,314 254,571 204,746 (458,853 ) 176,778 Less: Income from continuing operations attributable to noncontrolling interest — — 464 — 464 Net income attributable to common shareholders 176,314 254,571 204,282 (458,853 ) 176,314 Other comprehensive income attributable to common shareholders 15,806 8,387 12,277 (20,664 ) 15,806 Comprehensive income attributable to common shareholders $ 192,120 $ 262,958 $ 216,559 $ (479,517 ) $ 192,120
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 45,189 $ 748,412 $ 223,972 $ — $ 1,017,573 Accounts receivable, net 2,232 36,055 263,725 4,460 306,472 Accounts receivable from consolidated subsidiaries 9,095 2,273,240 359,560 (2,641,895 ) — Inventories, net — 236,355 174,561 (28,499 ) 382,417 Prepaid expenses and other current assets 15,492 8,722 24,048 3,337 51,599 Prepaid taxes — — 8,690 — 8,690 Total current assets 72,008 3,302,784 1,054,556 (2,662,597 ) 1,766,751 Property, plant and equipment, net 2,247 209,966 162,248 — 374,461 Goodwill — 902,429 983,728 — 1,886,157 Intangibles assets, net — 612,745 994,198 — 1,606,943 Investments in consolidated subsidiaries 7,245,740 1,801,602 23,546 (9,070,888 ) — Deferred tax assets — — 5,496 (3,476 ) 2,020 Notes receivable and other amounts due from consolidated subsidiaries 2,082,206 2,256,368 — (4,338,574 ) — Other assets 29,378 6,308 8,715 — 44,401 Total assets $ 9,431,579 $ 9,092,202 $ 3,232,487 $ (16,075,535 ) $ 5,680,733 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 27,250 $ — $ 50,000 $ — $ 77,250 Accounts payable 2,343 47,014 36,062 — 85,419 Accounts payable to consolidated subsidiaries 2,307,797 275,465 58,633 (2,641,895 ) — Accrued expenses 20,127 24,398 43,570 — 88,095 Current portion of contingent consideration — 591 — — 591 Payroll and benefit-related liabilities 19,973 28,011 40,107 — 88,091 Accrued interest 13,402 — 28 — 13,430 Income taxes payable 2,168 — 11,282 (593 ) 12,857 Other current liabilities 344 5,335 3,233 — 8,912 Total current liabilities 2,393,404 380,814 242,915 (2,642,488 ) 374,645 Long-term borrowings 2,172,805 — — — 2,172,805 Deferred tax liabilities 118,891 314,168 42,084 (3,476 ) 471,667 Pension and postretirement benefit liabilities 67,836 30,928 17,677 — 116,441 Noncurrent liability for uncertain tax positions 2,035 9,175 3,028 — 14,238 Notes payable and other amounts due to consolidated subsidiaries 2,178,181 1,954,051 206,342 (4,338,574 ) — Other liabilities 25,950 13,943 18,567 — 58,460 Total liabilities 6,959,102 2,703,079 530,613 (6,984,538 ) 3,208,256 Total shareholders' equity 2,472,477 6,389,123 2,701,874 (9,090,997 ) 2,472,477 Total liabilities and shareholders' equity $ 9,431,579 $ 9,092,202 $ 3,232,487 $ (16,075,535 ) $ 5,680,733 December 31, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 14,571 $ 1,031 $ 528,187 $ — $ 543,789 Accounts receivable, net 2,551 8,768 255,815 4,859 271,993 Accounts receivable from consolidated subsidiaries 4,861 2,176,059 309,149 (2,490,069 ) — Inventories, net — 200,852 140,406 (25,087 ) 316,171 Prepaid expenses and other current assets 14,239 5,332 17,474 3,337 40,382 Prepaid taxes — — 7,766 413 8,179 Assets held for sale — — 2,879 — 2,879 Total current assets 36,222 2,392,042 1,261,676 (2,506,547 ) 1,183,393 Property, plant and equipment, net 2,566 163,847 136,486 — 302,899 Goodwill — 708,546 568,174 — 1,276,720 Intangibles assets, net — 640,999 450,664 — 1,091,663 Investments in consolidated subsidiaries 6,022,042 1,519,031 23,685 (7,564,758 ) — Deferred tax assets 73,051 — 5,185 (76,524 ) 1,712 Notes receivable and other amounts due from consolidated subsidiaries 1,387,615 2,085,538 — (3,473,153 ) — Other assets 22,295 6,254 6,277 — 34,826 Total assets $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 133,071 $ — $ 50,000 $ — $ 183,071 Accounts payable 4,540 30,924 33,936 — 69,400 Accounts payable to consolidated subsidiaries 2,242,814 214,203 33,052 (2,490,069 ) — Accrued expenses 16,827 18,126 30,196 — 65,149 Current portion of contingent consideration — 587 — — 587 Payroll and benefit-related liabilities 20,610 26,672 35,397 — 82,679 Accrued interest 10,429 — 21 — 10,450 Income taxes payable 1,246 — 6,577 85 7,908 Other current liabilities 2,262 3,643 2,497 — 8,402 Total current liabilities 2,431,799 294,155 191,676 (2,489,984 ) 427,646 Long-term borrowings 850,252 — — — 850,252 Deferred tax liabilities — 316,526 31,375 (76,524 ) 271,377 Pension and postretirement benefit liabilities 85,645 31,561 15,856 — 133,062 Noncurrent liability for uncertain tax positions 1,169 13,684 2,667 — 17,520 Notes payable and other amounts due to consolidated subsidiaries 2,011,737 1,264,004 197,412 (3,473,153 ) — Other liabilities 23,848 15,695 12,472 — 52,015 Total liabilities 5,404,450 1,935,625 451,458 (6,039,661 ) 1,751,872 Convertible notes - redeemable equity component 1,824 — — — 1,824 Mezzanine equity 1,824 — — — 1,824 Total shareholders' equity 2,137,517 5,580,632 2,000,689 (7,581,321 ) 2,137,517 Total liabilities and shareholders' equity $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (156,643 ) $ 300,961 $ 237,308 $ (61,918 ) $ 319,708 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (233 ) (27,527 ) (26,217 ) — (53,977 ) Proceeds from sale of assets and investments 464,982 — 6,332 (464,982 ) 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (35,187 ) — (1,010,711 ) Net cash used in investing activities from continuing operations (510,775 ) (27,527 ) (55,072 ) (464,982 ) (1,058,356 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,963,500 — — — 1,963,500 Reduction in borrowings (747,576 ) — — — (747,576 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 4,739 — — — 4,739 Payments for contingent consideration — (245 ) — — (245 ) Dividends paid (45,905 ) — — — (45,905 ) Intercompany transactions (456,468 ) 474,192 (482,706 ) 464,982 — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 699,176 473,947 (544,624 ) 526,900 1,155,399 Cash flows from discontinued operations: Net cash used in operating activities (1,140 ) — — — (1,140 ) Net cash used in discontinued operations (1,140 ) — — — (1,140 ) Effect of exchange rate changes on cash and cash equivalents — — 58,173 — 58,173 Net increase in cash and cash equivalents 30,618 747,381 (304,215 ) — 473,784 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 45,189 $ 748,412 $ 223,972 $ — $ 1,017,573 Nine Months Ended September 25, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (72,542 ) $ 123,249 $ 253,166 $ (2,275 ) $ 301,598 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (191 ) (15,713 ) (20,008 ) — (35,912 ) Proceeds from sale of assets 5,607 49,571 1,451 (46,837 ) 9,792 Payments for businesses and intangibles acquired, net of cash acquired — (10,305 ) (50,572 ) 46,837 (14,040 ) Net cash (used in) provided by investing activities from continuing operations 5,416 23,553 (69,129 ) — (40,160 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 665,000 — 6,700 — 671,700 Reduction in borrowings (714,487 ) — — — (714,487 ) Debt extinguishment, issuance and amendment fees (8,958 ) — — — (8,958 ) Net proceeds from share based compensation plans and the related tax impacts 7,647 — — — 7,647 Payments to noncontrolling interest shareholders — — (464 ) — (464 ) Payments for contingent consideration — (133 ) — — (133 ) Payments for acquisition of noncontrolling interest — — (9,231 ) — (9,231 ) Dividends paid (43,980 ) — — — (43,980 ) Intercompany transactions 175,203 (145,645 ) (29,558 ) — — Intercompany dividends paid — — (2,275 ) 2,275 — Net cash provided by (used in) financing activities from continuing operations 80,425 (145,778 ) (34,828 ) 2,275 (97,906 ) Cash flows from discontinued operations: Net cash used in operating activities (1,451 ) — — — (1,451 ) Net cash used in discontinued operations (1,451 ) — — — (1,451 ) Effect of exchange rate changes on cash and cash equivalents — — (988 ) — (988 ) Net increase in cash and cash equivalents 11,848 1,024 148,221 — 161,093 Cash and cash equivalents at the beginning of the period 21,612 — 316,754 — 338,366 Cash and cash equivalents at the end of the period $ 33,460 $ 1,024 $ 464,975 $ — $ 499,459

New accounting standards (Detai

New accounting standards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income attributable to common shareholders	$ 77,015	$ 66,322	$ 195,188	$ 176,314
Net income (in dollars per share)	$ 1.65	$ 1.40	$ 4.18	$ 3.69
Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income attributable to common shareholders	$ 1,500		$ 5,900
Net income (in dollars per share)	$ 0.03		$ 0.13

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) $ / shares in Units, $ in Thousands	Sep. 15, 2017USD ($)	Apr. 03, 2017USD ($)	Jul. 31, 2016USD ($)	Oct. 01, 2017USD ($)	Jun. 26, 2016business	Jun. 26, 2016USD ($)	Oct. 01, 2017USD ($)Acquisition_number	Feb. 17, 2017USD ($)$ / shares	Dec. 31, 2016USD ($)	Jul. 01, 2016
Business Acquisition [Line Items]
Number of businesses acquired | Acquisition_number							3
Goodwill				$ 1,886,157			$ 1,886,157		$ 1,276,720
Tianjin Medis Medical Device Co. [Member]
Business Acquisition [Line Items]
Consideration transferred	$ 21,300
Goodwill	14,700
Pyng
Business Acquisition [Line Items]
Net assets acquired		$ 17,900
Vascular Solutions, Inc.
Business Acquisition [Line Items]
Goodwill								$ 522,614
Net assets acquired								$ 975,524
Business acquisition, share price (in dollars per share) | $ / shares								$ 56
Integration related costs				100			8,300
Post acquisition revenue				43,900			110,500
Post acquisition operating profit (loss)				$ 4,800			$ (6,800)
Teleflex Medical Private Limited
Business Acquisition [Line Items]
Ownership percentage										74.00%
Percentage of interests acquired										26.00%
Purchase price in excess of noncontrolling interest			$ 7,500
Medical Device and Supplies Distributors in New Zealand
Business Acquisition [Line Items]
Number of businesses acquired | business					2
2016 Acquisitions
Business Acquisition [Line Items]
Consideration transferred						$ 22,800
Intellectual Property, Customer Lists And A Non-Compete Agreement [Member] | Tianjin Medis Medical Device Co. [Member]
Business Acquisition [Line Items]
Consideration transferred	6,900
Intellectual property | Pyng
Business Acquisition [Line Items]
Consideration transferred		13,000
Customer lists | Pyng
Business Acquisition [Line Items]
Consideration transferred		$ 5,500
Estimated Fair Value Of Contingent Consideration One [Member] | Tianjin Medis Medical Device Co. [Member]
Business Acquisition [Line Items]
Consideration transferred, liabilities incurred	16,000
Estimated Fair Value Of Contingent Consideration Two [Member] | Tianjin Medis Medical Device Co. [Member]
Business Acquisition [Line Items]
Consideration transferred, liabilities incurred	$ 5,300

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Oct. 01, 2017	Feb. 17, 2017	Dec. 31, 2016
Assets
Goodwill	$ 1,886,157		$ 1,276,720
Vascular Solutions, Inc.
Assets
Current assets		$ 63,867
Property, plant and equipment		46,616
Intangible assets		539,250
Goodwill		522,614
Other assets		728
Total assets acquired		1,173,075
Less:
Current liabilities		15,079
Deferred tax liabilities		182,472
Liabilities assumed		197,551
Net assets acquired		$ 975,524

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Assets Acquired (Details) - Vascular Solutions, Inc. - USD ($) $ in Thousands	Feb. 17, 2017	Oct. 01, 2017
Business Acquisition [Line Items]
Fair value	$ 539,250
Intellectual property
Business Acquisition [Line Items]
Fair value	$ 248,200
Intellectual property | Minimum
Business Acquisition [Line Items]
Useful life range	10 years
Intellectual property | Maximum
Business Acquisition [Line Items]
Useful life range	20 years
In-process research and development (IPR&D)
Business Acquisition [Line Items]
Fair value	$ 15,600
Trade names
Business Acquisition [Line Items]
Fair value	16,650
Useful life range		20 years
Customer lists
Business Acquisition [Line Items]
Fair value	$ 258,800
Useful life range		25 years

Acquisitions - Pro Forma (Detai

Acquisitions - Pro Forma (Details) - Vascular Solutions, Inc. - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Business Acquisition [Line Items]
Net revenue	$ 534,703	$ 497,253	$ 1,574,021	$ 1,475,950
Net income	$ 76,194	$ 63,578	$ 209,630	$ 136,493
Net Income, Basic earnings per common share (in USD per share)	$ 1.69	$ 1.44	$ 4.66	$ 3.17
Net Income, Diluted earnings per common share (in USD per share)	$ 1.64	$ 1.34	$ 4.49	$ 2.85
Basic, weighted average common shares outstanding (in shares)	45,035	44,045	44,975	43,081
Diluted, weighted average common shares outstanding (in shares)	46,587	47,446	46,673	47,824

Restructuring (credits) charg43

Restructuring (credits) charges - Charges Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	$ (92)	$ 3,027	$ 13,723	$ 12,876
Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	(554)	2,784	12,807	12,027
Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	118	54	212	232
Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	104	107	238	114
Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	240	82	466	503
2017 Vascular Solutions integration program
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	(261)		4,626
2017 Vascular Solutions integration program | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	(319)		4,534
2017 Vascular Solutions integration program | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	0		0
2017 Vascular Solutions integration program | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	0		0
2017 Vascular Solutions integration program | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	58		92
2017 EMEA restructuring program
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	(630)		5,906
2017 EMEA restructuring program | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	(714)		5,822
2017 EMEA restructuring program | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	0		0
2017 EMEA restructuring program | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	0		0
2017 EMEA restructuring program | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	84		84
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	431	925	1,332	11,279
2016 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	274	851	1,099	10,919
2016 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	72	0	94	0
2016 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	0	0	(75)	0
2016 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	85	74	214	360
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	249	314	446
2014 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	197	308	379
2014 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	46	0	60
2014 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	0	0	0
2014 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	6	6	7
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	119	75	1,413	(15)
Other restructuring programs | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	8	(88)	973	(487)
Other restructuring programs | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	0	54	58	232
Other restructuring programs | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	104	107	313	114
Other restructuring programs | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges	$ 7	2	$ 69	126
2016 Other Restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges		1,713		1,713
2016 Other Restructuring programs | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges		1,713		1,713
2016 Other Restructuring programs | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges		0		0
2016 Other Restructuring programs | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges		0		0
2016 Other Restructuring programs | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges		$ 0		0
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges				(101)
2014 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges				(118)
2014 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges				0
2014 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges				0
2014 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring (credits) charges				$ 17

Restructuring (credits) charg44

Restructuring (credits) charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
2017 Vascular Solutions integration program
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 1.7		$ 1.7
2017 Vascular Solutions integration program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	6		6
2017 Vascular Solutions integration program | Minimum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4.5		4.5
2017 Vascular Solutions integration program | Minimum | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1.5		1.5
2017 Vascular Solutions integration program | Minimum | Retention Bonuses
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2.5		2.5
2017 Vascular Solutions integration program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7.5		7.5
2017 Vascular Solutions integration program | Maximum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	5.3		5.3
2017 Vascular Solutions integration program | Maximum | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2.2		2.2
2017 Vascular Solutions integration program | Maximum | Retention Bonuses
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3		3
2017 EMEA restructuring program
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	6		6
2017 EMEA restructuring program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7.1		7.1
2017 EMEA restructuring program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	8.5		8.5
2016 Other Restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment	1		1
Restructuring reserve	0.8		0.8
2016 Other Restructuring programs | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1.5		1.5
2016 Other Restructuring programs | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3.8		3.8
2016 Other Restructuring programs | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4.7		4.7
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	7.9		7.9
Aggregate restructuring charges incurred	13.8		13.8
2016 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1.4	$ 1.9	5.5	$ 4.2
Aggregate restructuring charges incurred	12		12
2016 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	34		34
Restructuring costs expected cash payment	27		27
2016 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	44		44
Restructuring costs expected cash payment	31		31
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	4.2		4.2
Restructuring expenses			25.9
Aggregate restructuring charges incurred	11.5		11.5
2014 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1	$ 2.5	3.1	$ 6.9
2014 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	43		43
Restructuring costs expected cash payment	33		33
Expected capital expenditures	24		24
2014 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	48		48
Restructuring costs expected cash payment	38		38
Expected capital expenditures	$ 30		$ 30

Restructuring (credits) charg45

Restructuring (credits) charges - Charges by segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ (92)	$ 3,027	$ 13,723	$ 12,876
Vascular North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	606	960	1,715	5,474
Anesthesia North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	220	946	1,031	3,185
Surgical North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	277	0	257
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(632)	89	6,503	3,012
OEM
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	187	0	191
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ (286)	$ 568	$ 4,474	$ 757

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Oct. 01, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 98,322	$ 65,319
Work-in-process	60,020	54,555
Finished goods	224,075	196,297
Inventories, net	$ 382,417	$ 316,171

Goodwill and other intangible47

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	9 Months Ended
	Oct. 01, 2017USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 1,276,720
Goodwill related to acquisitions	550,274
Currency translation and other adjustments	59,163
Goodwill, ending balance	1,886,157
Vascular North America
Goodwill [Roll Forward]
Goodwill, beginning balance	345,546
Goodwill related to acquisitions	0
Currency translation and other adjustments	(1,590)
Goodwill, ending balance	343,956
Anesthesia North America
Goodwill [Roll Forward]
Goodwill, beginning balance	141,253
Goodwill related to acquisitions	15,594
Currency translation and other adjustments	458
Goodwill, ending balance	157,305
Surgical North America
Goodwill [Roll Forward]
Goodwill, beginning balance	250,912
Goodwill related to acquisitions	0
Currency translation and other adjustments	0
Goodwill, ending balance	250,912
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	290,041
Goodwill related to acquisitions	9,139
Currency translation and other adjustments	33,665
Goodwill, ending balance	332,845
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	138,185
Goodwill related to acquisitions	2,927
Currency translation and other adjustments	8,585
Goodwill, ending balance	149,697
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	4,883
Goodwill related to acquisitions	0
Currency translation and other adjustments	0
Goodwill, ending balance	4,883
All Other
Goodwill [Roll Forward]
Goodwill, beginning balance	105,900
Goodwill related to acquisitions	522,614
Currency translation and other adjustments	18,045
Goodwill, ending balance	$ 646,559

Goodwill and other intangible48

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Oct. 01, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,151,308	$ 1,564,359
Accumulated Amortization	(544,365)	(472,696)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	34,296	16,532
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	901,367	622,428
Accumulated Amortization	(269,447)	(239,055)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	778,292	519,962
Accumulated Amortization	(238,236)	(203,390)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,637	23,021
Accumulated Amortization	(16,663)	(15,239)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	408,362	379,724
Accumulated Amortization	(18,343)	(13,974)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	5,354	2,692
Accumulated Amortization	$ (1,676)	$ (1,038)

Borrowings - Components of long

Borrowings - Components of long-term debt (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total borrowings	$ 2,262,000	$ 1,046,076
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017	0	(2,707)
Less: Unamortized debt issuance costs	(11,945)	(10,046)
Total long-term debt	2,250,055	1,033,323
Current borrowings	(77,250)	(183,071)
Long-term borrowings	2,172,805	850,252
Revolving Credit Facility
Debt Instrument [Line Items]
Senior Credit Facility:	$ 841,000	210,000
Line of credit facility interest rate	3.24%
Term Loan
Debt Instrument [Line Items]
Senior Credit Facility:	$ 721,000	0
Line of credit facility interest rate	3.24%
Senior Notes | 3.875% Convertible Senior Subordinated Notes due 2017
Debt Instrument [Line Items]
3.875% Convertible Senior Subordinated Notes due 2017	$ 0	136,076
Debt instrument, stated interest rate	3.875%
Senior Notes | 4.875% Senior Notes due 2026
Debt Instrument [Line Items]
Senior Notes	$ 400,000	400,000
Debt instrument, stated interest rate	4.875%
Senior Notes | 5.25% Senior Notes due 2024
Debt Instrument [Line Items]
Senior Notes	$ 250,000	250,000
Debt instrument, stated interest rate	5.25%
Securitization program, at a rate of 1.98% at October 1, 2017
Debt Instrument [Line Items]
Securitization program, at a rate of 1.98% at October 1, 2017	$ 50,000	$ 50,000
Debt instrument, stated interest rate	1.98%

Borrowings - Amended and restat

Borrowings - Amended and restated credit facility (Details)	Jan. 20, 2017USD ($)	Oct. 01, 2017USD ($)	Apr. 02, 2017USD ($)	Sep. 25, 2016USD ($)	Oct. 01, 2017USD ($)	Sep. 25, 2016USD ($)
Line of Credit Facility [Line Items]
Loss on extinguishment of debt		$ 0		$ 0	$ 5,593,000	$ 19,261,000
2017 Credit Agreement
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	2.00%
Maximum leverage ratio	4.50
Maximum secured leverage ratio	3.50
Minimum interest coverage ratio	3.50
Line of credit, debt issuance cost		$ 12,000,000			$ 12,000,000
2017 Credit Agreement | Revolving Credit Facility
Line of Credit Facility [Line Items]
Debt instrument term	5 years
Maximum borrowing capacity	$ 1,000,000,000
2017 Credit Agreement | Term Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 750,000,000
2013 Credit Agreement
Line of Credit Facility [Line Items]
Loss on extinguishment of debt			$ 400,000
London Interbank Offered Rate (LIBOR) | Minimum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.25%
London Interbank Offered Rate (LIBOR) | Maximum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	2.50%
Federal Funds Effective Swap Rate | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Adjusted LIBOR | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Adjusted LIBOR | Minimum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.25%
Adjusted LIBOR | Maximum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.50%

Borrowings - 3.875% Convertible

Borrowings - 3.875% Convertible Senior Subordinated Notes (Details) - USD ($)	Jan. 05, 2017	Oct. 01, 2017	Apr. 02, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016	Dec. 31, 2016
Short-term Debt [Line Items]
Repayments of debt					$ 747,576,000	$ 714,487,000
Conversion of convertible notes, shares issued upon conversion		500,000		1,300,000	500,000	1,900,000
Loss on extinguishment of debt		$ 0		$ 0	$ 5,593,000	$ 19,261,000
Shares delivered to the company by the counterparties to the convertible note hedge transactions					120,000
Number of securities called by warrants or rights (in shares)		724,648			724,648
Exercise Price of warrants (in USD per share)		$ 74.65			$ 74.65
Intrinsic value of warrants		$ 121,300,000			$ 121,300,000
Class Of Warrant Term							180 days
3.875% Convertible Senior Subordinated Notes due 2017 | Senior Notes
Short-term Debt [Line Items]
Extinguishment of debt, amount	$ 91,700,000
Principal amount of convertible debt	1,000
Repayments of debt	93,200,000
Repayments of debt, accrued interest	$ 1,500,000
Issued and delivered common stock to Holders	930,000
Loss on extinguishment of debt			$ 5,200,000
Convertible Debt [Member] | Convertible Notes Payable [Member] | Conversion [Member]
Short-term Debt [Line Items]
Conversion of convertible notes, shares issued upon conversion					500,000
Shares delivered to the company by the counterparties to the convertible note hedge transactions					500,000
Short-term Debt		44,300,000			$ 44,300,000
Aggregate principal amount of Convertible Notes tendered to the Company for conversion		$ 44,200,000			$ 44,200,000

Borrowings - Fair value of long

Borrowings - Fair value of long term debt (Details) - USD ($) $ in Thousands	Oct. 01, 2017	Dec. 31, 2016
Fair Value Measurements [Line Items]
Fair value of debt	$ 2,254,376	$ 1,274,127
Level 1
Fair Value Measurements [Line Items]
Fair value of debt	0	344,765
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$ 2,254,376	$ 929,362

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Net revenues	$ 534,703,000	$ 455,648,000	$ 1,551,197,000	$ 1,354,094,000
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Net revenues			96,000,000	95,800,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	0	0	0	0
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	76,100,000		76,100,000		$ 101,800,000
Foreign exchange contract | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Loss related to currency forward contracts	600,000	$ 100,000	3,700,000	$ 1,700,000
Total notional amount for all open foreign currency forward contracts	$ 112,300,000		$ 112,300,000		$ 73,400,000

Financial instruments - Fair va

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Oct. 01, 2017	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 2,002	$ 1,157
Total liability derivatives	330	2,257
Foreign exchange contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,002	1,157
Foreign exchange contract | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	330	2,257
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	1,684	667
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	237	2,139
Foreign exchange contract | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	318	490
Foreign exchange contract | Not Designated as Hedging Instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 93	$ 118

Financial instruments - Aggrega

Financial instruments - Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	1 Months Ended
	Jan. 31, 2017	Oct. 01, 2017	Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable		$ 10,084	$ 8,630
Allowance for doubtful accounts		3,100	2,000
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal		$ 50,613	$ 51,098
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal		16.90%	19.30%
Long-term portion of accounts receivable, net		$ 3,500	$ 2,700
Italy
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing receivable, significant sales	$ 16,100
Proceeds from sale of receivables	$ 16,000

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Oct. 01, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 8,563	$ 7,660
Derivative assets	2,002	1,157
Derivative liabilities	330	2,257
Contingent consideration liabilities	12,117	7,102
Current portion of contingent consideration	591	587
Fair value measurement with unobservable inputs reconciliations other liabilities	11,500	6,500
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	8,563	7,660
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	2,002	1,157
Derivative liabilities	330	2,257
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 12,117	$ 7,102

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	9 Months Ended
	Oct. 01, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 7,102
Additions	5,369
Payment	(245)
Revaluations	(109)
Ending balance	$ 12,117

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended			9 Months Ended
	Oct. 01, 2017	Apr. 02, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016	Dec. 31, 2016
Shareholders Equity [Line Items]
Investment warrants, exercise price (in dollars per share)		$ 74.65
Conversion of convertible notes, shares issued upon conversion	0.5		1.3	0.5	1.9
Convertible notes - redeemable equity component	$ 0			$ 0		$ 1,824
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.6		1.4	0.6	3.9
Convertible Note
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.1		1.5	0.4	2.3

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Debt Instrument [Line Items]
Basic (in shares)	45,035	44,045	44,975	43,081
Dilutive effect of share-based awards (in shares)	934	639	873	574
Dilutive effect of 3.875% Convertible Notes and warrants (in shares)	618	2,762	825	4,169
Diluted (in shares)	46,587	47,446	46,673	47,824
Senior Notes | 3.875% Convertible Senior Subordinated Notes due 2017
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.875%		3.875%

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			$ 2,137,517
Other comprehensive income (loss) before reclassifications			158,345	$ 9,494
Amounts reclassified from accumulated other comprehensive income	$ 182	$ 1,535	4,922	6,312
Net current-period other comprehensive income			163,267	15,806
Reclassification related to acquisition of noncontrolling interest				(832)
Ending Balance	2,472,477		2,472,477
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(2,424)	(2,491)
Other comprehensive income (loss) before reclassifications			3,383	(2,255)
Amounts reclassified from accumulated other comprehensive income			1,535	3,016
Net current-period other comprehensive income			4,918	761
Ending Balance	2,494	(1,730)	2,494	(1,730)
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(136,596)	(138,887)
Other comprehensive income (loss) before reclassifications			(1,050)	618
Amounts reclassified from accumulated other comprehensive income	1,124	1,187	3,387	3,296
Net current-period other comprehensive income			2,337	3,914
Ending Balance	(134,259)	(134,973)	(134,259)	(134,973)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(299,697)	(229,746)
Other comprehensive income (loss) before reclassifications			156,012	11,131
Amounts reclassified from accumulated other comprehensive income			0	0
Net current-period other comprehensive income			156,012	11,131
Reclassification related to acquisition of noncontrolling interest				(832)
Ending Balance	(143,685)	(219,447)	(143,685)	(219,447)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(438,717)	(371,124)
Ending Balance	$ (275,450)	$ (356,150)	$ (275,450)	$ (356,150)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 239,476	$ 214,046	$ 710,126	$ 630,946
Total before tax	(89,376)	(73,714)	(217,514)	(194,909)
Taxes on income from continuing operations	9,978	7,514	19,404	18,134
Net of tax	(79,398)	(66,200)	(198,110)	(176,775)
Total reclassifications, net of tax	182	1,535	4,922	6,312
Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,723	1,829	5,176	5,071
Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	20	15	79	43
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,743	1,844	5,255	5,114
Tax benefit	(619)	(657)	(1,868)	(1,818)
Total reclassifications, net of tax	1,124	1,187	3,387	3,296
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign exchange contract | Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(1,179)	535	1,769	3,907
Total before tax	(1,179)	535	1,769	3,907
Taxes on income from continuing operations	237	(187)	(234)	(891)
Net of tax	$ (942)	$ 348	$ 1,535	$ 3,016

Taxes on income from continui62

Taxes on income from continuing operations (Details)	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Income Tax Disclosure [Abstract]
Effective income tax rate	11.20%	10.20%	8.90%	9.30%

Pension and other postretirem63

Pension and other postretirement benefits (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 725	$ 656	$ 2,162	$ 1,963
Interest cost	3,773	3,948	11,347	11,797
Expected return on plan assets	(6,607)	(6,209)	(20,100)	(18,606)
Net amortization and deferral	1,668	1,781	5,049	4,937
Net benefits expense (income)	(441)	176	(1,542)	91
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	61	44	210	266
Interest cost	426	383	1,183	1,196
Expected return on plan assets	0	0	0	0
Net amortization and deferral	75	63	206	177
Net benefits expense (income)	$ 562	$ 490	$ 1,599	$ 1,639

Commitments and contingent li64

Commitments and contingent liabilities (Detail) $ in Thousands, ¥ in Millions	Oct. 18, 2017USD ($)	Mar. 24, 2017USD ($)	Mar. 24, 2017CNY (¥)	Dec. 05, 2014USD ($)	Oct. 01, 2017USD ($)	Dec. 31, 2016USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability					$ 8,600
Accrued expenses					$ 88,095	$ 65,149
Minimum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out					15 years
Maximum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out					20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies					$ 1,100
Other Liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies					5,800
Discontinued Operations
Loss Contingencies [Line Items]
Estimated litigation liability					5,000
Distributor vs Teleflex Medical Trading Company, Ltd.
Loss Contingencies [Line Items]
Damages sought		$ 7,500	¥ 51.2
Distributor vs Teleflex Medical Trading Company, Ltd. Repurchase of Inventory
Loss Contingencies [Line Items]
Damages sought		14,400	97.5
Teleflex Medical Trading Company, Ltd. vs Distributor - Outstanding Receivables
Loss Contingencies [Line Items]
Damages sought		$ 9,000	¥ 61.2
Parish of Calcasieu
Loss Contingencies [Line Items]
Accrued expenses					$ 5,000
Compensatory Damages | Judicial Ruling | Parish of Calcasieu
Loss Contingencies [Line Items]
Damages awarded				$ 100
Punitive Damages | Judicial Ruling | Parish of Calcasieu
Loss Contingencies [Line Items]
Damages awarded				$ 23,000
Subsequent Event | Punitive Damages | Settled Litigation [Member] | Parish of Calcasieu
Loss Contingencies [Line Items]
Damages awarded	$ 4,300

Segment information (Details)

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 534,703	$ 455,648	$ 1,551,197	$ 1,354,094
Operating profit	110,354	86,487	281,375	252,425
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	123,161	98,078	340,261	299,888
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(12,807)	(11,591)	(58,886)	(47,463)
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	90,979	85,118	278,350	254,817
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	25,212	21,781	75,286	63,431
Anesthesia North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	50,819	48,670	148,107	143,821
Anesthesia North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	15,684	13,954	49,727	41,181
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	40,804	41,827	131,464	123,904
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	13,618	14,050	47,285	39,654
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	131,517	121,398	394,212	375,198
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	24,187	16,576	69,677	61,563
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	72,387	64,087	185,328	176,434
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	20,217	18,072	49,619	52,831
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	48,589	41,418	137,067	115,693
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	12,256	10,201	31,714	24,605
All other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	99,608	53,130	276,669	164,227
All other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ 11,987	$ 3,444	$ 16,953	$ 16,623

Condensed consolidating guara66

Condensed consolidating guarantor financial information - Additional Information (Detail) - Senior Notes	Oct. 01, 2017
5.25% Senior Notes due 2024
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	5.25%
Ownership percentage	100.00%
4.875% Senior Notes due 2026
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	4.875%

Condensed consolidating guara67

Condensed consolidating guarantor financial information - Income and Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016	Oct. 01, 2017	Sep. 25, 2016
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 534,703	$ 455,648	$ 1,551,197	$ 1,354,094
Cost of goods sold	239,476	214,046	710,126	630,946
Gross profit	295,227	241,602	841,071	723,148
Selling, general and administrative expenses	163,771	139,797	486,674	419,128
Research and development expenses	21,194	15,067	59,299	42,892
Restructuring charges	(92)	3,027	13,723	12,876
Gain on sale of assets	0	(2,776)	0	(4,173)
(Loss) income from continuing operations before interest, extinguishment of debt and taxes	110,354	86,487	281,375	252,425
Interest, net	20,978	12,773	58,268	38,255
Loss on extinguishment of debt	0	0	5,593	19,261
Income from continuing operations before taxes	89,376	73,714	217,514	194,909
(Benefit) taxes on (loss) income from continuing operations	9,978	7,514	19,404	18,134
Equity in net income of consolidated subsidiaries	0	0	0	0
Income from continuing operations	79,398	66,200	198,110	176,775
Operating loss from discontinued operations	(3,749)	260	(4,597)	(116)
Benefit on loss from discontinued operations	(1,366)	138	(1,675)	(119)
(Loss) income from discontinued operations	(2,383)	122	(2,922)	3
Net income	77,015	66,322	195,188	176,778
Less: Income from continuing operations attributable to noncontrolling interest	0	0	0	464
Net income attributable to common shareholders	77,015	66,322	195,188	176,314
Other comprehensive income	43,845	1,053	163,267	15,806
Comprehensive income attributable to common shareholders	120,860	67,375	358,455	192,120
Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(104,024)	(96,220)	(315,085)	(289,247)
Cost of goods sold	(104,088)	(96,246)	(311,977)	(285,547)
Gross profit	64	26	(3,108)	(3,700)
Selling, general and administrative expenses	(126)	(29)	398	470
Research and development expenses	0	0	0	0
Restructuring charges	0	0	0	0
Gain on sale of assets		0		0
(Loss) income from continuing operations before interest, extinguishment of debt and taxes	190	55	(3,506)	(4,170)
Interest, net	0	0	0	0
Loss on extinguishment of debt			0	0
Income from continuing operations before taxes	190	55	(3,506)	(4,170)
(Benefit) taxes on (loss) income from continuing operations	6	(72)	(593)	(481)
Equity in net income of consolidated subsidiaries	(174,114)	(156,564)	(487,749)	(455,164)
Income from continuing operations	(173,930)	(156,437)	(490,662)	(458,853)
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
(Loss) income from discontinued operations	0	0	0	0
Net income	(173,930)		(490,662)	(458,853)
Less: Income from continuing operations attributable to noncontrolling interest				0
Net income attributable to common shareholders		(156,437)		(458,853)
Other comprehensive income	(86,482)	(742)	(327,288)	(20,664)
Comprehensive income attributable to common shareholders	(260,412)	(157,179)	(817,950)	(479,517)
Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	10,536	11,208	38,523	30,822
Research and development expenses	220	179	719	319
Restructuring charges	0	380	0	380
Gain on sale of assets		(2,707)		(2,707)
(Loss) income from continuing operations before interest, extinguishment of debt and taxes	(10,756)	(9,060)	(39,242)	(28,814)
Interest, net	53,521	41,344	152,268	107,534
Loss on extinguishment of debt			5,593	19,261
Income from continuing operations before taxes	(64,277)	(50,404)	(197,103)	(155,609)
(Benefit) taxes on (loss) income from continuing operations	(30,845)	(18,017)	(83,867)	(56,942)
Equity in net income of consolidated subsidiaries	112,830	98,544	311,346	275,296
Income from continuing operations	79,398	66,157	198,110	176,629
Operating loss from discontinued operations	(3,749)	260	(4,597)	(495)
Benefit on loss from discontinued operations	(1,366)	95	(1,675)	(180)
(Loss) income from discontinued operations	(2,383)	165	(2,922)	(315)
Net income	77,015		195,188	176,314
Less: Income from continuing operations attributable to noncontrolling interest				0
Net income attributable to common shareholders		66,322		176,314
Other comprehensive income	43,845	1,053	163,267	15,806
Comprehensive income attributable to common shareholders	120,860	67,375	358,455	192,120
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	335,051	270,610	989,314	809,951
Cost of goods sold	194,262	163,052	576,465	489,293
Gross profit	140,789	107,558	412,849	320,658
Selling, general and administrative expenses	89,315	80,333	278,529	248,195
Research and development expenses	14,788	8,422	39,568	23,501
Restructuring charges	552	1,712	7,261	7,027
Gain on sale of assets		104		(274)
(Loss) income from continuing operations before interest, extinguishment of debt and taxes	36,134	16,987	87,491	42,209
Interest, net	(33,392)	(29,612)	(96,776)	(72,367)
Loss on extinguishment of debt			0	0
Income from continuing operations before taxes	69,526	46,599	184,267	114,576
(Benefit) taxes on (loss) income from continuing operations	23,453	13,166	60,061	39,347
Equity in net income of consolidated subsidiaries	61,027	57,837	175,690	179,342
Income from continuing operations	107,100	91,270	299,896	254,571
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
(Loss) income from discontinued operations	0	0	0	0
Net income	107,100		299,896	254,571
Less: Income from continuing operations attributable to noncontrolling interest				0
Net income attributable to common shareholders		91,270		254,571
Other comprehensive income	30,196	(501)	147,727	8,387
Comprehensive income attributable to common shareholders	137,296	90,769	447,623	262,958
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	303,676	281,258	876,968	833,390
Cost of goods sold	149,302	147,240	445,638	427,200
Gross profit	154,374	134,018	431,330	406,190
Selling, general and administrative expenses	64,046	48,285	169,224	139,641
Research and development expenses	6,186	6,466	19,012	19,072
Restructuring charges	(644)	935	6,462	5,469
Gain on sale of assets		(173)		(1,192)
(Loss) income from continuing operations before interest, extinguishment of debt and taxes	84,786	78,505	236,632	243,200
Interest, net	849	1,041	2,776	3,088
Loss on extinguishment of debt			0	0
Income from continuing operations before taxes	83,937	77,464	233,856	240,112
(Benefit) taxes on (loss) income from continuing operations	17,364	12,437	43,803	36,210
Equity in net income of consolidated subsidiaries	257	183	713	526
Income from continuing operations	66,830	65,210	190,766	204,428
Operating loss from discontinued operations	0	0	0	379
Benefit on loss from discontinued operations	0	43	0	61
(Loss) income from discontinued operations	0	(43)	0	318
Net income	66,830		190,766	204,746
Less: Income from continuing operations attributable to noncontrolling interest				464
Net income attributable to common shareholders		65,167		204,282
Other comprehensive income	56,286	1,243	179,561	12,277
Comprehensive income attributable to common shareholders	$ 123,116	$ 66,410	$ 370,327	$ 216,559

Condensed consolidating guara68

Condensed consolidating guarantor financial information - Balance Sheets (Details) - USD ($) $ in Thousands	Oct. 01, 2017	Dec. 31, 2016	Sep. 25, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 1,017,573	$ 543,789	$ 499,459	$ 338,366
Accounts receivable, net	306,472	271,993
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	382,417	316,171
Prepaid expenses and other current assets	51,599	40,382
Prepaid taxes	8,690	8,179
Assets held for sale	0	2,879
Total current assets	1,766,751	1,183,393
Property, plant and equipment, net	374,461	302,899
Goodwill	1,886,157	1,276,720
Intangible assets, net	1,606,943	1,091,663
Investments in consolidated subsidiaries	0	0
Deferred tax assets	2,020	1,712
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	44,401	34,826
Total assets	5,680,733	3,891,213
Current liabilities
Current borrowings	77,250	183,071
Accounts payable	85,419	69,400
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	88,095	65,149
Current portion of contingent consideration	591	587
Payroll and benefit-related liabilities	88,091	82,679
Accrued interest	13,430	10,450
Income taxes payable	12,857	7,908
Other current liabilities	8,912	8,402
Total current liabilities	374,645	427,646
Long-term borrowings	2,172,805	850,252
Deferred tax liabilities	471,667	271,377
Pension and postretirement benefit liabilities	116,441	133,062
Noncurrent liability for uncertain tax positions	14,238	17,520
Notes payable and other amounts due to consolidated subsidiaries	0	0
Other liabilities	58,460	52,015
Total liabilities	3,208,256	1,751,872
Convertible notes - redeemable equity component	0	1,824
Mezzanine equity	0	1,824
Total shareholders' equity	2,472,477	2,137,517
Total liabilities and shareholders' equity	5,680,733	3,891,213
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	4,460	4,859
Accounts receivable from consolidated subsidiaries	(2,641,895)	(2,490,069)
Inventories, net	(28,499)	(25,087)
Prepaid expenses and other current assets	3,337	3,337
Prepaid taxes	0	413
Assets held for sale		0
Total current assets	(2,662,597)	(2,506,547)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investments in consolidated subsidiaries	(9,070,888)	(7,564,758)
Deferred tax assets	(3,476)	(76,524)
Notes receivable and other amounts due from consolidated subsidiaries	(4,338,574)	(3,473,153)
Other assets	0	0
Total assets	(16,075,535)	(13,620,982)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(2,641,895)	(2,490,069)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	(593)	85
Other current liabilities	0	0
Total current liabilities	(2,642,488)	(2,489,984)
Long-term borrowings	0	0
Deferred tax liabilities	(3,476)	(76,524)
Pension and postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due to consolidated subsidiaries	(4,338,574)	(3,473,153)
Other liabilities	0	0
Total liabilities	(6,984,538)	(6,039,661)
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	(9,090,997)	(7,581,321)
Total liabilities and shareholders' equity	(16,075,535)	(13,620,982)
Parent Company
Current assets
Cash and cash equivalents	45,189	14,571	33,460	21,612
Accounts receivable, net	2,232	2,551
Accounts receivable from consolidated subsidiaries	9,095	4,861
Inventories, net	0	0
Prepaid expenses and other current assets	15,492	14,239
Prepaid taxes	0	0
Assets held for sale		0
Total current assets	72,008	36,222
Property, plant and equipment, net	2,247	2,566
Goodwill	0	0
Intangible assets, net	0	0
Investments in consolidated subsidiaries	7,245,740	6,022,042
Deferred tax assets	0	73,051
Notes receivable and other amounts due from consolidated subsidiaries	2,082,206	1,387,615
Other assets	29,378	22,295
Total assets	9,431,579	7,543,791
Current liabilities
Current borrowings	27,250	133,071
Accounts payable	2,343	4,540
Accounts payable to consolidated subsidiaries	2,307,797	2,242,814
Accrued expenses	20,127	16,827
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	19,973	20,610
Accrued interest	13,402	10,429
Income taxes payable	2,168	1,246
Other current liabilities	344	2,262
Total current liabilities	2,393,404	2,431,799
Long-term borrowings	2,172,805	850,252
Deferred tax liabilities	118,891	0
Pension and postretirement benefit liabilities	67,836	85,645
Noncurrent liability for uncertain tax positions	2,035	1,169
Notes payable and other amounts due to consolidated subsidiaries	2,178,181	2,011,737
Other liabilities	25,950	23,848
Total liabilities	6,959,102	5,404,450
Convertible notes - redeemable equity component		1,824
Mezzanine equity		1,824
Total shareholders' equity	2,472,477	2,137,517
Total liabilities and shareholders' equity	9,431,579	7,543,791
Guarantor Subsidiaries
Current assets
Cash and cash equivalents	748,412	1,031	1,024	0
Accounts receivable, net	36,055	8,768
Accounts receivable from consolidated subsidiaries	2,273,240	2,176,059
Inventories, net	236,355	200,852
Prepaid expenses and other current assets	8,722	5,332
Prepaid taxes	0	0
Assets held for sale		0
Total current assets	3,302,784	2,392,042
Property, plant and equipment, net	209,966	163,847
Goodwill	902,429	708,546
Intangible assets, net	612,745	640,999
Investments in consolidated subsidiaries	1,801,602	1,519,031
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,256,368	2,085,538
Other assets	6,308	6,254
Total assets	9,092,202	7,516,257
Current liabilities
Current borrowings	0	0
Accounts payable	47,014	30,924
Accounts payable to consolidated subsidiaries	275,465	214,203
Accrued expenses	24,398	18,126
Current portion of contingent consideration	591	587
Payroll and benefit-related liabilities	28,011	26,672
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	5,335	3,643
Total current liabilities	380,814	294,155
Long-term borrowings	0	0
Deferred tax liabilities	314,168	316,526
Pension and postretirement benefit liabilities	30,928	31,561
Noncurrent liability for uncertain tax positions	9,175	13,684
Notes payable and other amounts due to consolidated subsidiaries	1,954,051	1,264,004
Other liabilities	13,943	15,695
Total liabilities	2,703,079	1,935,625
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	6,389,123	5,580,632
Total liabilities and shareholders' equity	9,092,202	7,516,257
Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	223,972	528,187	$ 464,975	$ 316,754
Accounts receivable, net	263,725	255,815
Accounts receivable from consolidated subsidiaries	359,560	309,149
Inventories, net	174,561	140,406
Prepaid expenses and other current assets	24,048	17,474
Prepaid taxes	8,690	7,766
Assets held for sale		2,879
Total current assets	1,054,556	1,261,676
Property, plant and equipment, net	162,248	136,486
Goodwill	983,728	568,174
Intangible assets, net	994,198	450,664
Investments in consolidated subsidiaries	23,546	23,685
Deferred tax assets	5,496	5,185
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	8,715	6,277
Total assets	3,232,487	2,452,147
Current liabilities
Current borrowings	50,000	50,000
Accounts payable	36,062	33,936
Accounts payable to consolidated subsidiaries	58,633	33,052
Accrued expenses	43,570	30,196
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	40,107	35,397
Accrued interest	28	21
Income taxes payable	11,282	6,577
Other current liabilities	3,233	2,497
Total current liabilities	242,915	191,676
Long-term borrowings	0	0
Deferred tax liabilities	42,084	31,375
Pension and postretirement benefit liabilities	17,677	15,856
Noncurrent liability for uncertain tax positions	3,028	2,667
Notes payable and other amounts due to consolidated subsidiaries	206,342	197,412
Other liabilities	18,567	12,472
Total liabilities	530,613	451,458
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	2,701,874	2,000,689
Total liabilities and shareholders' equity	$ 3,232,487	$ 2,452,147

Condensed consolidating guara69

Condensed consolidating guarantor financial information - Cash Flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2017	Sep. 25, 2016
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 319,708	$ 301,598
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(53,977)	(35,912)
Proceeds from sale of assets	6,332	9,792
Payments for businesses and intangibles acquired, net of cash acquired	(1,010,711)	(14,040)
Net cash used in investing activities from continuing operations	(1,058,356)	(40,160)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,963,500	671,700
Reduction in borrowings	(747,576)	(714,487)
Debt extinguishment, issuance and amendment fees	(19,114)	(8,958)
Net proceeds from share based compensation plans and the related tax impacts	4,739	7,647
Payments to noncontrolling interest shareholders	0	464
Payments for contingent consideration	(245)	(133)
Payments for acquisition of noncontrolling interest	0	(9,231)
Dividends paid	(45,905)	(43,980)
Intercompany transactions	0	0
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	1,155,399	(97,906)
Cash flows from discontinued operations:
Net cash used in operating activities	(1,140)	(1,451)
Net cash used in discontinued operations	(1,140)	(1,451)
Effect of exchange rate changes on cash and cash equivalents	58,173	(988)
Net increase in cash and cash equivalents	473,784	161,093
Cash and cash equivalents at the beginning of the period	543,789	338,366
Cash and cash equivalents at the end of the period	1,017,573	499,459
Eliminations
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(61,918)	(2,275)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	0	0
Proceeds from sale of assets	(464,982)	(46,837)
Payments for businesses and intangibles acquired, net of cash acquired	0	46,837
Net cash used in investing activities from continuing operations	(464,982)	0
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments to noncontrolling interest shareholders		0
Payments for contingent consideration	0	0
Payments for acquisition of noncontrolling interest		0
Dividends paid	0	0
Intercompany transactions	464,982	0
Intercompany dividends paid	61,918	2,275
Net cash provided by (used in) financing activities from continuing operations	526,900	2,275
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	0	0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(156,643)	(72,542)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(233)	(191)
Proceeds from sale of assets	464,982	5,607
Payments for businesses and intangibles acquired, net of cash acquired	(975,524)	0
Net cash used in investing activities from continuing operations	(510,775)	5,416
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,963,500	665,000
Reduction in borrowings	(747,576)	(714,487)
Debt extinguishment, issuance and amendment fees	(19,114)	(8,958)
Net proceeds from share based compensation plans and the related tax impacts	4,739	7,647
Payments to noncontrolling interest shareholders		0
Payments for contingent consideration	0	0
Payments for acquisition of noncontrolling interest		0
Dividends paid	(45,905)	(43,980)
Intercompany transactions	(456,468)	175,203
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	699,176	80,425
Cash flows from discontinued operations:
Net cash used in operating activities	(1,140)	(1,451)
Net cash used in discontinued operations	(1,140)	(1,451)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	30,618	11,848
Cash and cash equivalents at the beginning of the period	14,571	21,612
Cash and cash equivalents at the end of the period	45,189	33,460
Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	300,961	123,249
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(27,527)	(15,713)
Proceeds from sale of assets	0	49,571
Payments for businesses and intangibles acquired, net of cash acquired	0	(10,305)
Net cash used in investing activities from continuing operations	(27,527)	23,553
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments to noncontrolling interest shareholders		0
Payments for contingent consideration	(245)	(133)
Payments for acquisition of noncontrolling interest		0
Dividends paid	0	0
Intercompany transactions	474,192	(145,645)
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	473,947	(145,778)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	747,381	1,024
Cash and cash equivalents at the beginning of the period	1,031	0
Cash and cash equivalents at the end of the period	748,412	1,024
Non-Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	237,308	253,166
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(26,217)	(20,008)
Proceeds from sale of assets	6,332	1,451
Payments for businesses and intangibles acquired, net of cash acquired	(35,187)	(50,572)
Net cash used in investing activities from continuing operations	(55,072)	(69,129)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	6,700
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments to noncontrolling interest shareholders		464
Payments for contingent consideration	0	0
Payments for acquisition of noncontrolling interest		(9,231)
Dividends paid	0	0
Intercompany transactions	(482,706)	(29,558)
Intercompany dividends paid	(61,918)	(2,275)
Net cash provided by (used in) financing activities from continuing operations	(544,624)	(34,828)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	58,173	(988)
Net increase in cash and cash equivalents	(304,215)	148,221
Cash and cash equivalents at the beginning of the period	528,187	316,754
Cash and cash equivalents at the end of the period	$ 223,972	$ 464,975

Subsequent events (Details)

Subsequent events (Details) - Subsequent Event - NeoTract $ in Millions	Oct. 02, 2017USD ($)
Subsequent Event [Line Items]
Cash payment to acquire business	$ 725
Additional payment upon achievement of certain commercial sales milestones	$ 375